

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number
WO 03/037896 A1(51) International Patent Classification⁷: C07D 453/00,
487/08, 498/04, 519/00, 451/04, 471/08, A61K 31/445 //
(C07D 487/08, 209:00, 209:00) (C07D 498/04, 221:00,
263:00) (C07D 519/00, 209:00, 209:00, 221:00, 317:00)
(C07D 519/00, 209:00, 209:00, 221:00, 263:00) (C07D
519/00, 221:00, 221:00, 221:00, 317:00)(71) Applicant (for all designated States except US): PHAR-
MACIA & UPJOHN COMPANY [US/US]; 301 Henri-
etta Street, Kalamazoo, MI 49001 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WALKER, Daniel,
P. [US/US]; 9350 Highlandview Drive, Kalamazoo,
MI 49009 (US). JACOBSEN, Eric, Jon [US/US];
6233 Bethany Circle, Richland, MI 49083 (US). PI-
OTROWSKI, David, W. [US/US]; 3248 Lost Pine Way,
Portage, MI 49024 (US). WISHKA, Donn, G. [US/US];
1431 Northampton Road, Kalamazoo, MI 49006 (US).
CORBETT, Jeffrey, W. [US/US]; 6427 Pepperidge
Circle, Portage, MI 49024 (US). GROPI, Vincent, E.,
Jr. [US/US]; 318 Sprague Avenue, Kalamazoo, MI 49006
(US). ACKER, Brad, A. [US/US]; 1734 Tanager Lane,
Kalamazoo, MI 49009 (US). RAUCKHORST, Mark, R.
[US/US]; 3749 Tartan Circle, Portage, MI 49024 (US).

(21) International Application Number: PCT/US02/31579

(22) International Filing Date: 17 October 2002 (17.10.2002)


(25) Filing Language: English

(26) Publication Language: English




(30) Priority Data:
60/344,436 26 October 2001 (26.10.2001) US
60/342,674 21 December 2001 (21.12.2001) US

[Continued on next page]

(54) Title: N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS



Formula (I)

(57) Abstract: The invention provides compounds of Formula (I), wherein Azabicyclo is I, II, III, IV, V, or VI; W⁰ is a bicyclic moiety and is (a), (b) or (c). These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.



(74) Agent: HOSLEY, Mary, J.; Global Intellectual Property, Pharmacia & Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS

FIELD OF INVENTION

5 Nicotinic acetylcholine receptors (nAChRs) play a large role in central nervous system (CNS) activity. Particularly, they are known to be involved in cognition, learning, mood, emotion, and neuroprotection. There are several types of nicotinic acetylcholine receptors, and each one appears to have a different role in regulating CNS function. Nicotine affects all such receptors, and has a variety of activities.

10 Unfortunately, not all of the activities are desirable. In fact, one of the least desirable properties of nicotine is its addictive nature and the low ratio between efficacy and safety. The present invention relates to molecules that have a greater effect upon the $\alpha 7$ nAChRs as compared to other closely related members of this large ligand-gated receptor family. Thus, the invention provides compounds that are active drug

15 molecules with fewer side effects.

BACKGROUND OF THE INVENTION

 Cell surface receptors are, in general, excellent and validated drug targets. nAChRs comprise a large family of ligand-gated ion channels that control neuronal

20 activity and brain function. These receptors have a pentameric structure. In mammals, this gene family is composed of nine alpha and four beta subunits that co-assemble to form multiple subtypes of receptors that have a distinctive pharmacology. Acetylcholine is the endogenous regulator of all of the subtypes, while nicotine non-selectively activates all nAChRs.

25 The $\alpha 7$ nAChR is one receptor system that has proved to be a difficult target for testing. Native $\alpha 7$ nAChR is not routinely able to be stably expressed in most mammalian cell lines (Cooper and Millar, *J. Neurochem.*, 1997, 68(5):2140-51). Another feature that makes functional assays of $\alpha 7$ nAChR challenging is that the receptor is rapidly (100 milliseconds) inactivated. This rapid inactivation greatly

30 limits the functional assays that can be used to measure channel activity.

 Recently, Eisele et al. has indicated that a chimeric receptor formed between the N-terminal ligand binding domain of the $\alpha 7$ nAChR (Eisele et al., *Nature*, 366(6454), p 479-83, 1993), and the pore forming C-terminal domain of the 5-HT₃

receptor expressed well in *Xenopus* oocytes while retaining nicotinic agonist sensitivity. Eisele et al. used the N-terminus of the avian (chick) form of the $\alpha 7$ nAChR receptor and the C-terminus of the mouse form of the 5-HT₃ gene. However, under physiological conditions the $\alpha 7$ nAChR is a calcium channel while the 5-HT₃R is a sodium and potassium channel. Indeed, Eisele et al. teaches that the chicken $\alpha 7$ nAChR/ mouse 5-HT₃R behaves quite differently than the native $\alpha 7$ nAChR with the pore element not conducting calcium but actually being blocked by calcium ions. WO 00/73431 A2 reports on assay conditions under which the 5-HT₃R can be made to conduct calcium. This assay may be used to screen for agonist activity at this receptor.

US Patent 6,054,464 discloses azabicyclic esters of carbamic acids useful in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, as well as intermediates and use of intermediates in synthesis.

US Patent 5,977,144 discloses compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the $\alpha 7$ receptor subtype with little or no activation of the $\alpha 4\beta 2$ or other receptor subtypes.

US Patent 5,599,937 discloses heteroaromatic quinuclidines used for treating diseases related to muscarinic receptor function.

US Patent 5,561,149 discloses the use of a mono or bicyclic carbocyclic, or heterocyclic carboxylic acid, ester or amide or an imidazolyl carbazol in the manufacture of a medicament suitable for the treatment of stress-related psychiatric disorders, for increasing vigilance, for the treatment of rhinitis or serotonin-induced disorders and/or coadministration with another active agent to increase the bioavailability thereof, or for nasal administration.

US Patent 5,543,426 discloses the use of certain 3,7-disubstituted indole compounds for treating depression or cognitive disorders.

US Patent 5,434,161 discloses imidazopyridines as serotonergic 5-HT₃ antagonists.

US Patent 5,362,740 discloses dihydrobenzofuran carboxamides useful in treating CNS disorders, but motility disorders, and/or emesis and/or pain in mammals, and/or migraine.

US Patent 5,352,685 discloses thieno[3,2-b]pyridine derivatives effective for the prevention and therapeutical treatment of the symptoms caused by gastric hypanakinesis, such as heartburn, abdominal distension feeling, anorexia, unpleasant feeling on upper abdomen, abdominalgia, nausea, vomiting, etc. caused by the underlying diseases such as acute and chronic gastritis, stomach and duodenum ulcer, gastroneurosis, gastroparesis, etc.

US Patent 5,342,845 discloses indole derivatives and drugs. The compound of the invention is disclosed as being effective as a gastrointestinal motor activity regulator, antimigraine, antipsychotic or antianxiety drug and for dementia or orthostatic hypotension.

US Patent 5,322,951 discloses certain 1-(2,3-dihydro-indole)carbonyl intermediates useful for preparing 1-(2,3-dihydro)-1-carboxamide final products that possess 5-HT M-receptor antagonist activity.

US Patent 5,175,173 discloses carboxamides useful as antiemetic or antipsychotic agents.

US Patent 5,114,947 discloses method for alleviating anxiety using benzobicyclic carboxamides.

US Patent 5,063,231 discloses method of treatment of visceral pain.

US Patent 5,039,680 discloses 5-HT₃ antagonists in preventing or reducing dependency on dependency-inducing agents.

US Patent 5,001,133 discloses substituted benzoic acid heterocyclic amides and esters as being serotonin M antagonists.

US Patent 4,985,437 discloses the use of certain compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT₃ receptors for the treatment of cognitive disorders such as attentional and memory deficits and dementia states.

US Patent 4,983,600 discloses heterocyclic compounds useful as 5-HT₃ antagonists.

US Patent 4,973,594 discloses the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT₃ receptors for the treatment of depression.

US Patent 4,937,247 discloses 1-acyl indazoles that are disclosed as having 5-HT₃ antagonist activity.

US Patent 4,935,511 discloses benzoxazine and benzoxazepin carboxamide 5-HT₃ antagonists properties including CNS, anti-emetic and gastric prokinetic activity and which are void of any significant D₂ receptor binding affinity.

US Patent 4,933,445 discloses heteroazabenzobicyclic carboxamide 5-HT₃ antagonists properties including CNS, anti-emetic and gastric prokinetic activity.

US Patent 4,921,982 discloses 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids which are useful as intermediates for 5-HT₃ antagonists.

US Patent 4,920,227 discloses benzobicyclic carboxamide 5-HT₃ antagonists.

US Patent 4,920,219 discloses substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their valuable use as 5-HT₃ antagonists having CNS and gastric prokinetic activity void of any significant D₂ receptor binding properties.

US Patent 4,920,127 discloses substituted indoles and their use as 5-HT₃ receptor antagonists.

US Patent 4,910,193 discloses treatment of gastrointestinal disorders.

US Patent 4,882,327 discloses certain heterocyclic N-substituted carboxamides having 5-HT₃ receptor antagonist activity.

US Patent 4,863,919 discloses a method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes.

US Patent 4,835,162 discloses agonists and antagonists to nicotine as smoking deterrents.

US Patent 4,822,795 discloses pharmaceutically useful esters and amides.

US Patent 4,803,199 discloses pharmaceutically useful heterocyclic acid esters and amides or alkylene bridged piperidines as serotonin M antagonists.

US Patent 4,798,829 discloses 1-azabicyclo[3.2.2]nonane derivatives having gastric motility enhancing activity and/or anti-emetic activity and/or 5-HT receptor antagonist activity.

US Patent 4,797,406 discloses amides and esters containing bridged piperidines and use as serotonin M antagonists.

US Patent 4,721,720 discloses a method of treating emesis, anxiety and/or irritable bowel syndrome.

US Patent 4,612,319 discloses bridged quinolizinidinylamides, compositions containing them and methods for their use.

US Patent 4,605,652 discloses a method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes, and the
5 pharmaceutically acceptable acid addition salts, hydrates and alcoholates thereof.

WO 01/76576 A1 discloses a pharmaceutical composition for treatment of acute, chorinc pain and/or neuropathic pain migraines.

WO 01/60821 A1 discloses novel abiarylcarboxamides and their use in therapy, especially in the treatement of prophylaxis of psychotic and intellectual
10 impairment conditions.

WO 01/36417 A1 discloses novel N-azabicyclo-amide derivatives and use in therapy, especially in the treatment of prophylaxis of psychotic disorders and intellectual impairment disorders.

WO 00/73431 A2 discloses two binding assays to directly measure the affinity
15 and selectivity of compounds at the $\alpha 7$ nAChR and the 5-HT₃R. The combined use of these functional and binding assays may be used to identify compounds that are selective agonists of the $\alpha 7$ nAChR.

WO 97/35860 discloses novel benzimidazol derivatives having an affinity for the serotonergic 5-HT₃/5-HT₄ receptors.

WO 96/33186 discloses substituted dihydrobenzofuran derivatives as 5-HT₄
20 agonists.

WO 95/27490 discloses serotonin antagonists (5-HT₃) for treating fibromyalgia.

WO 92/10494 discloses novel compounds having pharmacological activity, to
25 a process for their preparation and their use as pharmaceuticals.

WO 91/17161 discloses isoquinoline amides and esters as 5-HT₃ receptor antagonists.

WO 91/09593 discloses 5-HT₃ antagonists for treatment of nausea, bradycardia or hypotension associated myocardial instability.

WO 90/14347 A as abstracted in chemical abstract 1991:143,158 discloses N-
30 quinuclidinyl-indolecarboxamide derivatives as being antiemetics.

EP 512 350 A2 discloses 3-(indolyl-2-carboxamido) quinuclidines useful for treating diseases characterized by an excess or enhanced sensitivity to serotonin, e.g.,

psychosis, nausea, vomiting, dementia or other cognitive diseases, migraine, diabetes. The compound may be used to control anxiety, aggression, depression, and pain. The compounds are disclosed as serotonin 5-HT₃ antagonists.

EP 496 064 A1 discloses a process for the preparation of substituted
5 benzofuran derivatives. The compounds are disclosed as being useful 5-HT₃ receptor antagonists.

EP 483 836 A1 discloses pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives, their preparation process, and serotonin receptor antagonists containing them as active ingredients.

10 EP 403 882 A2 discloses indole derivatives which have pharmacological activities such as 5-HT antagonism and the like.

EP 279 512 discloses the use of certain 5-HT₃ receptor antagonists in the treatment of visceral pain.

DE 3810552 A1 discloses esters and amides of indolyl-, benzo[b]thiophenyl-,
15 benzo[b]furancarboxylic acids or 4-amino-2 methoxy-benzoic acids with N-heterocyclic or N-heterobicyclic alcohols or amines. The compounds disclosed have activity against pain especially migraine, as an anti-arrhythmic for gastrointestinal disturbances, stomach disturbances, gastritis ulcer, gall bladder, spastic colon, Crohn's disease, ulcerative colitis, carcinoid syndrome, diarrhea of various types. The
20 compounds are also disclosed as speeding stomach emptying, controlling gastro duodenal and gastro esophageal reflux, disturbances of esophageal motility, hiatal hernia, cardiac insufficiency, hypotonic stomach, paralytic ileus, manic depressive psychosis and other psychoses. The compounds are also disclosed as useful for stress related diseases, senility, and enhancement of nasal absorption of other agents, e.g., in
25 the treatment of emesis.

In *Bioorg. & Med. Chem. Lett.* 11 (2001) 319-321, the 5-HT₃ antagonist tropisetron (ICS 205-930) is discussed as a potent and selective $\alpha 7$ nicotinic receptor partial agonist.

In *Behavioral Brain Res.*, 113 (2000) 169-181, it is discussed that the brain $\alpha 7$
30 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease using DMXBA which is known as GTS-21.

In *Bioorg. & Med. Chem. Lett.* 9 (1999) 1895-1900, it is discussed the discovery of a highly potent, functionally-selective muscarinic M₁ agonist.


In *Bioorg. & Med. Chem. Lett.* 4 (1994) 695-698, it is discussed pyrazolo[1,5-a]pyridines and pyrazolo[1,5-b]pyridazines as 5-HT₃ antagonists.

In *Eur. J. med. Chem.* 34 (1999) 415-422, it is discussed benzimidazole-2-carboxylic acid amides and esters as a new structural class of 5-HT₃ ligands.

5

SUMMARY OF THE INVENTION

The present invention discloses compounds of the Formula I:




Formula I

10

wherein X is O, or S;

Each R₁ is H, alkyl, cycloalkyl, halogenated alkyl, substituted phenyl, or substituted naphthyl;

Azabicyclo is



15

R₀ is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl;

Each R₂ is independently alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl, or R₂ is absent provided that k₂, k₅, or k₆ is 0;


k₂ is 0 or 1;

k₅ and k₆ are independently 0, 1, or 2;

20

R₂₋₃ is H, alkyl, halogenated alkyl, substituted alkyl, F, Cl, Br, or I;

W⁰ is a bicyclic moiety and is



W is C(H) where

- V---Z---Y is selected from O-C(R₃)=N, O-C(R₅)₂-N(R₄), O-C(R₅)₂-S,
 5 O-N=C(R₅), O-C(R₅)(R₈)-O, O-C(R₅)₂-O, C(R₅)₂-O-C(R₅)₂, S-C(R₃)=N,
 S-C(R₅)₂-N(R₄), S-N=C(R₅), N=C(R₃)-O, N=C(R₃)-S, N=C(R₃)-N(R₄),
 N(R₄)-N=C(R₅), N(R₄)-C(R₅)₂-O, N(R₄)-C(R₅)₂-S, N(R₄)-C(R₅)₂-N(R₄),
 C(R₅)₂-O-N(R₄), C(R₅)₂-S-C(R₅)₂, C(R₅)₂-N(R₄)-C(R₅)₂, C(R₅)₂-N(R₄)-O,
 C(R₅)₂-N(R₄)-S, C(R₅)=N-O, C(R₅)=N-S, C(R₅)=N-N(R₄),
 10 C(R₅)(R₁₇)-C(R₃)(R₁₇)-C(R₅)(R₁₇), or C(R₅)₂-C(R₃)(R₅)-C(R₅)₂;

W is N where

- V---Z---Y is selected from O-C(R₃)=N, O-C(R₅)₂-N(R₄), O-C(R₅)₂-S,
 O-N=C(R₅), O-C(R₅)₂-O, S-C(R₃)=N, S-C(R₅)₂-N(R₄), S-N=C(R₅), N=C(R₃)-O,
 N=C(R₃)-S, N=C(R₃)-N(R₄), N(R₄)-N=C(R₃), N(R₄)-C(R₅)₂-O, N(R₄)-C(R₅)₂-S,
 15 N(R₄)-C(R₅)₂-N(R₄), C(R₅)₂-O-N(R₄), C(R₅)₂-N(R₄)-O, C(R₅)₂-N(R₄)-S,
 C(R₅)=N-O, C(R₅)=N-S, C(R₃)=N-N(R₄), C(R₅)=C(R₃)-O, C(R₅)=C(R₃)-S,
 C(R₅)=C(R₅)-N(R₄), C(R₅)=C(R₅)-C(R₅)₂, or C(R₅)₂-C(R₃)(R₅)-C(R₅)₂;

- W¹, W², W³, and W⁴ are each independently N or C(R₂₁), provided that no
 more than two of W¹, W², W³, and W⁴ are N and further provided when more than
 20 two of W¹, W², W³, and W⁴ are C(R₂₁) that no more than two R₂₁ are other than H;

J is N(R₂₃), S, or O;

Q is N(R₁₉), O, or S;

- Each R₃ is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted
 alkyl, cycloalkyl, lactam heterocycloalkyl, phenoxy, substituted phenoxy, R₇, R₉,
 25 -N(R₄)-aryl, -N(R₄)-halogenated phenyl, -N(R₄)-halogenated naphthyl,
 -O-halogenated phenyl, -O-substituted phenyl, -O-halogenated naphthyl,
 -O-substituted naphthyl, -S-halogenated phenyl, -S-substituted phenyl, -S-halogenated
 naphthyl, -S-substituted naphthyl, or alkyl substituted on the ω carbon with R₁₅ where
 said ω carbon is determined by counting the longest carbon chain of the alkyl moiety
 30 with the C-1 carbon being the carbon attached to the bicyclic moiety W⁰ and the ω


carbon being the carbon furthest, e.g., separated by the greatest number of carbon atoms in the chain, from said C-1 carbon;

Each R_4 is H, or alkyl;


Each R_5 is independently H, F, alkyl, substituted alkyl, halogenated alkyl,
 5 alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl,
 halogenated alkynyl, cycloalkyl, $-C(O)NH_2$, $-CO_2R_1$, or aryl;

R_6 is H, F, Br, I, Cl, $-CN$, $-CF_3$, $-OR_{16}$, $-SR_{16}$, or $-N(R_{16})_2$;


R_7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of $-O-$, $=N-$,
 10 $-N(R_{19})-$, and $-S-$, and having 0-1 substituent selected from R_{20} and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R_7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula



15 wherein A_1 is O, S, or NR_{19} ,



wherein A is CR_{18} or N, A_2 and A_3 are independently selected from CR_{18} , $C(R_{18})_2$, O, S, N, or NR_{19} , provided that both A_2 and A_3 are not simultaneously O, simultaneously S, or simultaneously O and S, or



20

wherein A_2 and A_3 are independently selected from CR_{18} , $C(R_{18})_2$, O, S, N, or NR_{19} , and A is CR_{18} or N, each 9-membered fused-ring moiety having 0-1 substituent selected from R_{20} and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, and having a bond directly or indirectly attached to the core molecule
 25 where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;

Each R_8 is independently F, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, cycloalkyl, $-C(O)NH_2$, $-CO_2R_1$, or aryl;

R_9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R_{20} and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R_9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R_{20} and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond directly or indirectly attached to the core molecule where valency allows;

Each R_{10} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{13} , cycloalkyl substituted with 1 substituent selected from R_{13} , heterocycloalkyl substituted with 1 substituent selected from R_{13} , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;

Each R_{11} is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;

R_{13} is $-OR_{11}$, $-SR_{11}$, $-N(R_{11})_2$, $-C(O)R_{11}$, $-C(O)NR_{11}R_{11}$, $-CN$, $-CF_3$, $-NR_{11}C(O)R_{11}$, $-S(O)_2N(R_{11})_2$, $-NR_{11}S(O)_2R_{11}$, or $-NO_2$;

R_{15} is aryl, R_7 , or R_9 ;

R_{16} is H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, substituted phenyl, or substituted naphthyl;

One of R_{17} is H, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, $-CN$, F, Br, Cl, I, $-OR_1$, $-C(O)NH_2$, $-NHR_1$, $-SR_1$, $-CO_2R_1$, aryl, R_7 , or R_9 , and each of the other two R_{17} is independently alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, $-CN$, F, Br, Cl, I, $-OR_1$, $-C(O)NH_2$, $-NHR_1$, $-SR_1$, $-CO_2R_1$, aryl, R_7 , or R_9 ;

Each R_{18} is independently selected from H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, $-OR_{11}$, $-SR_{11}$, $-NR_{11}R_{11}$, $-C(O)R_{11}$, $-NO_2$, $-C(O)N(R_{11})_2$, $-CN$, $-NR_{11}C(O)R_{11}$, $-S(O)_2N(R_{11})_2$, F, Cl, Br, or I,

-NR₁₁S(O)₂R₁₁, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₁₁, -SR₁₁, -NR₁₁R₁₁, -C(O)R₁₁, -NO₂, -C(O)NR₁₁R₁₁, -CN, -NR₁₁C(O)R₁₁, -S(O)₂NR₁₁R₁₁, or -NR₁₁S(O)₂R₁₁, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;

R₁₉ is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R₂₀ and further having 0-3 substituents independently selected from F, Cl, Br, or I;

R₂₀ is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, -OR₁₁, -SR₁₁, -NR₁₁R₁₁, -C(O)R₁₁, -C(O)NR₁₁R₁₁, -CN, -NR₁₁C(O)R₁₁, -S(O)₂NR₁₁R₁₁, -NR₁₁S(O)₂R₁₁, -NO₂, alkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R₁₃, cycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R₁₃, or heterocycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or -R₁₃;

R₂₁ is H, F, Cl, Br, I, alkyl, substituted alkyl, halogenated alkyl, cycloalkyl, -CN, -NR₂₂R₂₂, -OR₂₂, or -SR₂₂;

Each R₂₂ is independently H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, substituted cycloalkyl, heterocycloalkyl, or substituted heterocycloalkyl;

R₂₃ is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, naphthyl, substituted naphthyl, R₇, or R₉;

or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.

Embodiments of the invention may include one or more or combination of the following.

An embodiment of the present invention provides a use of a compound of Formula I for treating a disease or condition, wherein the diseases, disorders, and/or

condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit
5 hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies,
10 Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

15 In another aspect, the invention includes treating a mammal suffering from schizophrenia or psychosis by administering compounds of Formula I in conjunction with antipsychotic drugs (also called anti-psychotic agents). The compounds of the present invention and the antipsychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously the compounds of the
20 present invention and the antipsychotic drugs can be incorporated into a single pharmaceutical composition. Alternatively, two separate compositions, i.e., one containing compounds of the present invention and the other containing antipsychotic drugs, can be administered simultaneously.

The present invention also includes the compounds of the present invention,
25 pharmaceutical compositions containing the active compounds as the free base or as a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, and methods to treat the identified diseases.

A further embodiment of the present invention provides a method comprising administering a therapeutically effective amount of a compound of the present
30 invention or a pharmaceutical composition contains said compound to the mammal.

The compound of Formula I, wherein X is O.

The compound of Formula I, where X is S.

The compound of Formula I, where Azabicyclo is any one or more of I, II, III, IV, V, or VI.

The compound of Formula I, where W^0 is any one or more of (a), (b), or (c).

The compound of Formula I, where W is C(H), and where V---Z---Y is any one or more of the following: O-C(R₃)=N, O-C(R₅)₂-N(R₄), O-C(R₅)₂-S,
 5 O-N=C(R₅), O-C(R₅)(R₈)-O, O-C(R₅)₂-O, C(R₅)₂-O-C(R₅)₂, S-C(R₃)=N,
 S-C(R₅)₂-N(R₄), S-N=C(R₅), N=C(R₃)-O, N=C(R₃)-S, N=C(R₃)-N(R₄),
 N(R₄)-N=C(R₅), N(R₄)-C(R₅)₂-O, N(R₄)-C(R₅)₂-S, N(R₄)-C(R₅)₂-N(R₄),
 C(R₅)₂-O-N(R₄), C(R₅)₂-S-C(R₅)₂, C(R₅)₂-N(R₄)-C(R₅)₂, C(R₅)₂-N(R₄)-O,
 10 C(R₅)₂-N(R₄)-S, C(R₅)=N-O, C(R₅)=N-S, C(R₅)=N-N(R₄),
 C(R₅)(R₁₇)-C(R₃)(R₁₇)-C(R₅)(R₁₇), or C(R₅)₂-C(R₃)(R₅)-C(R₅)₂.

The compound of Formula I, where W is N, and where V---Z---Y is any one or more of the following: O-C(R₃)=N, O-C(R₅)₂-N(R₄), O-C(R₅)₂-S,
 O-N=C(R₅), O-C(R₅)₂-O, S-C(R₃)=N, S-C(R₅)₂-N(R₄), S-N=C(R₅), N=C(R₃)-O,
 15 N=C(R₃)-S, N=C(R₃)-N(R₄), N(R₄)-N=C(R₃), N(R₄)-C(R₅)₂-O, N(R₄)-C(R₅)₂-S,
 N(R₄)-C(R₅)₂-N(R₄), C(R₅)₂-O-N(R₄), C(R₅)₂-N(R₄)-O, C(R₅)₂-N(R₄)-S,
 C(R₅)=N-O, C(R₅)=N-S, C(R₃)=N-N(R₄), C(R₅)=C(R₃)-O, C(R₅)=C(R₃)-S,
 C(R₅)=C(R₅)-N(R₄), C(R₅)=C(R₅)-C(R₅)₂, or C(R₅)₂-C(R₃)(R₅)-C(R₅)₂.

The compound of Formula I, where each R₃ is independently any one of the following: H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl,
 20 lactam heterocycloalkyl, phenoxy, substituted phenoxy, R₇, R₉, -N(R₄)-aryl,
 -N(R₄)-halogenated phenyl, -N(R₄)-halogenated naphthyl, -O-halogenated phenyl,
 -O-substituted phenyl, -O-halogenated naphthyl, -O-substituted naphthyl,
 -S-halogenated phenyl, -S-substituted phenyl, -S-halogenated naphthyl, -S-substituted
 25 naphthyl, or alkyl substituted on the ω carbon with R₁₅ where said ω carbon is
 determined by counting the longest carbon chain of the alkyl moiety with the C-1
 carbon being the carbon attached to the bicyclic moiety W^0 and the ω carbon being the
 carbon furthest, e.g., separated by the greatest number of carbon atoms in the chain,
 from said C-1 carbon;

30 The compound of Formula I, where each R₄ is H. The compound of Formula I, where each R₄ is alkyl. The compound of Formula I, where one R₄ is alkyl and the other is H or alkyl.

The compound of Formula I, where each R_5 is independently H, F, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, cycloalkyl, $-C(O)NH_2$, $-CO_2R_1$, or aryl.

5 The compound of Formula I, where each R_8 is independently F, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, cycloalkyl, $-C(O)NH_2$, $-CO_2R_1$, or aryl.

10 The compound of Formula I, where one R_{17} is H, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, $-CN$, F, Br, Cl, I, $-CF_3$, $-OR_1$, $-C(O)NH_2$, $-NHR_1$, $-SR_1$, $-CO_2R_1$, aryl, R_7 , or R_9 , and each of the other two R_{17} is independently alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, $-CN$, F, Br, Cl, I, $-CF_3$,
15 $-OR_1$, $-C(O)NH_2$, $-NHR_1$, $-SR_1$, $-CO_2R_1$, aryl, R_7 , or R_9 .

Another group of compounds of Formula I includes compounds wherein W^0 includes any one or more of the following: 1,3-oxazolo[4,5-c]pyridin-6-yl, 1,3-oxazolo[5,4-c]pyridin-6-yl, 1,3-dioxolo[4,5-c]pyridin-6-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,2-benzisothiazol-5-yl, 1,2-benzisothiazol-6-yl, 1,3-thiazolo[4,5-c]pyridin-6-yl, 1,3-thiazolo[5,4-c]pyridin-6-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzodioxol-5-yl, 1*H*-benzimidazole-5-yl, 1*H*-indazol-5-yl, 1*H*-indazol-6-yl, indan-5-yl, 2-benzisothiophen-5-yl, 2*H*-isoindole-5-yl, 2-benzofuran-5-yl, 1,3-benzothiazol-2-yl, or 1*H*-imidazo[4,5-c]pyridin-6-yl, any of which is optionally substituted with R_3 , R_4 , R_5 , R_8 , or R_{17} as allowed by the definition
25 of Formula I. One of ordinary skill in the art will recognize where the optional substitution is allowed by comparing the listed moieties with W^0 .

Another embodiment includes compounds where W^0 includes any one or more of the following: 1,3-oxazolo[4,5-c]pyridin-6-yl, 1,3-oxazolo[5,4-c]pyridin-6-yl, 1,3-dioxolo[4,5-c]pyridin-6-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,2-benzisothiazol-5-yl, 1,2-benzisothiazol-6-yl, 1,3-thiazolo[4,5-c]pyridin-6-yl, 1,3-thiazolo[5,4-c]pyridin-6-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzodioxol-5-yl, 1*H*-benzimidazole-5-yl, 1*H*-indazol-5-yl, 1*H*-indazol-6-yl, indan-5-yl, 2-benzisothiophen-5-yl, 2*H*-isoindole-5-yl, 2-benzofuran-5-yl, 1,3-benzothiazol-

2-yl, or 1*H*-imidazo[4,5-*c*]pyridin-6-yl, any of which is optionally substituted with lower cycloalkyl or lower alkyl optionally substituted with to 4 halogens, and further optionally substituted with up to 1 substituent selected from -OR₁₀, -N(R₁₀)₂, -C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀,

5 -NR₁₀S(O)₂R₁₀, wherein each R₁₀ is independently selected from lower alkyl or halogenated lower alkyl.

Another embodiment includes compounds where W⁰ includes any one or more of the following: 1,3-oxazolo[4,5-*c*]pyridin-6-yl, 1,3-oxazolo[5,4-*c*]pyridin-6-yl, 1,3-dioxolo[4,5-*c*]pyridin-6-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,2-
10 benzisothiazol-5-yl, 1,2-benzisothiazol-6-yl, 1,3-thiazolo[4,5-*c*]pyridin-6-yl, 1,3-thiazolo[5,4-*c*]pyridin-6-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzodioxol-5-yl, 1*H*-benzimidazole-5-yl, 1*H*-indazol-5-yl, 1*H*-indazol-6-yl, indan-5-yl, 2-benzisothiophen-5-yl, 2*H*-isoindole-5-yl, 2-benzofuran-5-yl, 1,3-benzothiazol-2-yl, or 1*H*-imidazo[4,5-*c*]pyridin-6-yl, when Azabicyclo is II.

15 The compound of Formula I, where Q is N(R₁₉), O, or S.

Another embodiment includes compounds where W¹, W², W³, and W⁴ are each C(H) or N. Another embodiment includes compounds where W¹, W², W³, and W⁴ are each C(H). Another embodiment includes compounds where J is S.

The present invention also includes the compounds of the present invention,
20 pharmaceutical compositions containing the active compounds, and methods to treat the identified diseases.

The present invention also includes a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. The pharmaceutical composition is
25 administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval. The pharmaceutical composition is administered to deliver a compound of the present invention in an amount of from about 0.001 to about 100 mg/kg of body weight of said mammal per day. The pharmaceutical composition is also administered to deliver a compound of the present invention in an
30 amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day.

A pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, an anti-psychotic agent, and a pharmaceutically acceptable excipient. The pharmaceutical composition is

administered to independently administer said compound and said agent rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval.

The pharmaceutical composition is administered to deliver a compound of the present invention in an amount of from about 0.001 to about 100 mg/kg of body weight of
5 said mammal per day. The pharmaceutical composition is also administered to deliver a compound of the present invention in an amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day.

The present invention also includes a use of a compound according to Formula I or pharmaceutically acceptable salt thereof for the preparation of a medicament for
10 treating a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist.


The present invention also includes a use of a compound according to Formula I or pharmaceutically acceptable salt thereof for the preparation of a medicament for
15 treating a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist, wherein the disease, or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease,
20 pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated
25 with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related
30 macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

The present invention also includes a method for treating a disease or condition in a mammal in need thereof, wherein the mammal would receive

symptomatic relief from the administration of an $\alpha 7$ nicotinic acetylcholine receptor agonist comprising administering to the mammal a therapeutically effective amount of a compound according to Formula I or pharmaceutically acceptable salt thereof.


The present invention also includes a method for treating a disease or
5 condition in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound according to Formula I or pharmaceutically acceptable salt thereof, wherein the disease or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease,
10 pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated
15 with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related
20 macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

The compounds of Formula I (Azabicyclo is I) have optically active centers on the quinuclidine ring. The compounds of the present invention include quinuclidines with the 3R configuration and also includes racemic mixtures and compositions of
25 varying degrees of stereochemical purities. For example, and not by limitation, compounds of Formula I include compounds with stereospecificity including:




The compounds of Formula I (Azabicyclo is II) have optically active center(s) on the [2.2.1] azabicyclic ring at C3 and C4. The scope of this invention includes

racemic mixtures and the separate stereoisomers of Formula I being *endo*-4*S*, *endo*-4*R*, *exo*-4*S*, *exo*-4*R*:



- 5 The *endo* isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges. The *exo* isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges. Thus, there can be four separate isomers: *exo*-4(*R*), *exo*-4(*S*), *endo*-4(*R*), and *endo*-4(*S*).
- 10 4(*S*).

The compounds of Formula I (Azabicyclo III) have optically active center(s) on the [2.2.1] azabicyclic ring at C1, C4 and C5. The scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being (1*R*,4*R*,5*S*), (1*R*,4*R*,5*R*), (1*S*,4*S*,5*R*), (1*S*,4*S*,5*S*):




15

The *endo* isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges. The *exo* isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges.

20 Thus, there can be four separate isomers: *exo*-(1*R*,4*R*,5*S*), *exo*-(1*S*,4*S*,5*R*), *endo*-(1*S*,4*S*,5*S*), *endo*-(1*R*,4*R*,5*R*).

The compounds of Formula I (Azabicyclo IV) have optically active center(s) on the [2.2.1] azabicyclic ring at C1, C4 and C6. The scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being *exo*-(1*S*,4*R*,6*S*), *exo*-(1*R*,4*S*,6*R*), *endo*-(1*S*,4*R*,6*R*), and *endo*-(1*R*,4*S*,6*S*):

25




The *endo* isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges.


The *exo* isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges.

- 5 Thus, there can be four separate isomers: *exo*-(1*S*,4*R*,6*S*), *exo*-(1*R*,4*S*,6*R*), *endo*-(1*S*,4*R*,6*R*), and *endo*-(1*R*,4*S*,6*S*).

The compounds of Formula I (Azabicyclo is V) have optically active center(s) on the [3.2.1] azabicyclic ring at C3 and C5. The scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being *endo*-3*S*, 5*R*,
 10 *endo*-3*R*, 5*S*, *exo*-3*R*, 5*R*, *exo*-3*S*, 5*S*:



The compounds of Formula I (Azabicyclo is VI) have optically active centers on the [3.2.2] azabicyclic ring with one center being at C3 when R₂ is absent. The
 15 scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being 3(*S*) and 3(*R*):




20 The compounds of the present invention having the specified stereochemistry have different levels of activity and that for a given set of values for the variable substituents one isomer may be preferred over the other isomers. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required. This invention involves racemic mixtures and compositions of varying
 25 degrees of stereochemical purities when the Azabicyclo is substituted with only the amide/thioamide or is substituted with substituents in addition to the amide/thioamide, e.g., k is 1 or 2. This invention involves racemic mixtures and compositions of varying degrees of stereochemical purities. When racemic mixtures and compositions are referenced, it means racemic mixtures and compositions of varying degree of

stereochemical purities. It is preferred to carry out stereoselective syntheses and/or to subject the reaction product to appropriate purification steps so as to produce substantially optically pure materials. Suitable stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions. Naming a specific isomer includes racemic mixtures thereof within the scope of this invention. Therefore, naming *N*-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide, includes *N*-(*exo*-4(*rac*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide; *N*-(3(*rac*),4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide, and *N*-(1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide.


Stereoselective syntheses and/or subjecting the reaction product to appropriate purification steps produces substantially optically pure materials. Suitable stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions.

Another embodiment of the compounds of Formula I includes any one or more or combination of the following configurations for compounds:




where (i) the compound is a racemic mixture, or
 (ii) the compound has the *R* stereochemistry at C-3 as discussed herein and stereochemistry is unspecified at C-6.

Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for compounds:



where (i) k_2 is 0 (R_2 is absent);
 (ii) R_2 has any definition discussed herein;
 (iii) R_2 has any definition discussed herein; or
 (iv) the 2.2.1 moiety has the *exo*-4(*S*) stereochemistry as discussed herein.

Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for compounds:




where (i) R_{2-3} is H;

5 (ii) R_{2-3} is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, or substituted phenyl or substituted naphthyl; or

 (iii) R_{2-3} is alkyl, halogenated alkyl, substituted alkyl, or substituted phenyl or substituted naphthyl.

Another embodiment of compounds of Formula I includes any one or more or
10 combination of the following configurations for compounds:




where (i) R_{2-3} is H;

 (ii) R_{2-3} is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, or substituted phenyl or substituted naphthyl; or

15 (iii) R_{2-3} is alkyl, halogenated alkyl, substituted alkyl, or substituted phenyl or substituted naphthyl.

Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for compounds:



20 where (i) k_5 is 0 (R_2 is absent);


 (ii) R_2 is absent and where the Azabicyclo has the stereochemistry of 3R, 5R;

 (iii) k_5 is 2, where R_{2-a} is alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl, and where R_{2-b} is alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;

(iv) k_5 is 1, where R_2 is alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl; or

(v) k_5 is 1, where R_2 is alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl.

5 Another embodiment of compounds of Formula I includes any one or more or combination of the following configurations for compounds:



where (i) k_6 is 0 (R_2 is absent);

(ii) k_6 is 2, where each R_{2-a} is alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl, and where each R_{2-b} is alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;

(iii) k_6 is 1, where R_2 is alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl; or

(iv) k_6 is 1, where R_2 is alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl.

The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutically acceptable salt thereof as a pure enantiomer or racemic mixture thereof:

- N*-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide;
 20 *N*-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzothiazole-6-carboxamide;
N-[(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-indane-5-carboxamide;
N-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzodioxole-5-carboxamide;
N-[(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1*H*-indazole-5-carboxamide;
N-[(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1*H*-indazole-6-carboxamide;
 25 *N*-[(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
 or *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide.

The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutically acceptable salt thereof as a pure enantiomer or racemic mixture thereof:

- 30 *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzoxazole-5-carboxamide;

- N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzoxazole-6-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-2-methyl-1,3-benzoxazole-6-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzothiazole-6-carboxamide;
5 *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)indane-5-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzodioxole-5-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1*H*-indazole-5-carboxamide;
10 *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1*H*-indazole-6-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
N-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
N-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-6-carboxamide;
15 *N*-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-6-carboxamide;
N-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
20 *N*-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-6-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-6-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzothiazole-6-carboxamide;
25 *N*-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)indane-5-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzodioxole-5-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
30 *N*-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1*H*-indazole-5-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1*H*-indazole-6-carboxamide;

- N*-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzoxazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzoxazole-5-carboxamide;
- 5 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzoxazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzoxazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]indane-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzodioxole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
- 10 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-indazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-indazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
- N*-((3*R*)-1-azabicyclo[3.2.2]nonan-3-yl)-1,3-benzoxazole-5-carboxamide;
- N*-((3*R*)-1-azabicyclo[3.2.2]nonan-3-yl)-1,3-benzothiazole-6-carboxamide;
- 15 *N*-((3*R*)-1-azabicyclo[3.2.2]nonan-3-yl)indane-5-carboxamide;
- N*-((3*R*)-1-azabicyclo[3.2.2]nonan-3-yl)-1,3-benzodioxole-5-carboxamide;
- N*-[(3*R*)-1-azabicyclo[3.2.2]nonan-3-yl]-1*H*-indazole-6-carboxamide; or
- N*-[(3*R*)-1-azabicyclo[3.2.2]nonan-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide.

The compound of Formula I, where the compound is any one or more or
20 combination of the following as the free base, or pharmaceutally acceptable salt thereof as a pure enantiomer or racemic mixture thereof:

- N*-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1,2-benzisothiazole-6-carboxamide;
- N*-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1,2-benzisothiazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-indazole-5-carboxamide;
- 25 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1*H*-indazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1*H*-indazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethyl-1*H*-indazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethyl-1*H*-indazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,2-benzisothiazole-6-carboxamide;
- 30 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,2-benzisothiazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethyl-1,2-benzisothiazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethyl-1,2-benzisothiazole-5-carboxamide;

- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1,2-benzisothiazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1,2-benzisothiazole-5-carboxamide;
- 5 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyclopropyl-1,3-benzoxazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyclopropyl-1,3-benzoxazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyclopropyl-1,3-benzothiazole-6-
- 10 carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyclopropyl-1,3-benzothiazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzothiazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzothiazole-5-carboxamide;
- 15 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethyl-1,3-benzothiazole-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethyl-1,3-benzothiazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzodioxole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethyl-1,3-benzodioxole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2,2-dimethyl-1,3-benzodioxole-5-
- 20 carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-thiazolo[5,4-*c*]pyridine-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-thiazolo[4,5-*c*]pyridine-6-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
- 25 or *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-oxazolo[4,5-*c*]pyridine-6-carboxamide.

The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutally acceptable salt

30 thereof as a pure enantiomer or racemic mixture thereof:

- N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-2-benzoisothiophene-5-benzamide;
- N*-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-2-benzoisothiophene-5-benzamide;

- N*-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-2-benzisothiophene-5-benzamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-benzisothiophene-5-benzamide;
- N*-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-2-benzofuran-5-carboxamide;
- 5 *N*-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-2*H*-isoindole-5-carboxamide;
- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-benzofuran-5-carboxamide; or *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2*H*-isoindole-5-carboxamide;

The compound of Formula I, where the compound is any one or more or
10 combination of the following as the free base, or pharmaceutally acceptable salt thereof as a pure enantiomer or racemic mixture thereof:

- N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzoxazole-5-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-5-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzoxazole-6-carboxamide;
- 15 *N*-(2-azabicyclo[2.2.1]hept-5-yl)-2-methyl-1,3-benzoxazole-6-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzothiazole-6-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-5-yl)indane-5-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzodioxole-5-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
- 20 *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1*H*-indazole-5-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-5-yl)-1*H*-indazole-6-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-6-yl)-1,3-benzoxazole-5-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-6-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
- 25 *N*-(2-azabicyclo[2.2.1]hept-6-yl)-1,3-benzoxazole-6-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-6-yl)-2-methyl-1,3-benzoxazole-6-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-6-yl)-1,3-benzothiazole-6-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-6-yl)indane-5-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-6-yl)-1,3-benzodioxole-5-carboxamide;
- 30 *N*-(2-azabicyclo[2.2.1]hept-6-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-6-yl)-1*H*-indazole-5-carboxamide;
- N*-(2-azabicyclo[2.2.1]hept-6-yl)-1*H*-indazole-6-carboxamide; or
- N*-(2-azabicyclo[2.2.1]hept-6-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide.

The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutally acceptable salt thereof as a pure enantiomer or racemic mixture thereof:

- 5 *N*-(2-azabicyclo[2.2.1]hept-5-yl)-2-benzothiothiophene-5-benzamide; or
N-(2-azabicyclo[2.2.1]hept-6-yl))-2-benzothiothiophene-5-benzamide.

The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutally acceptable salt thereof as a pure enantiomer or racemic mixture thereof:


- 10 *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzothiazole-2-carboxamide;
N-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1,3-benzothiazole-2-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzothiazole-2-carboxamide;
 15 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-2-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-imidazo[4,5-*c*]pyridine-6-carboxamide;
N-[(3*R*)-1-azabicyclo[3.2.2]nonan-3-yl]-1,3-benzothiazole-2-carboxamide;
N-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzothiazole-2-carboxamide; or
N-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-benzothiazole-2-carboxamide.

20

Further aspects and embodiments of the invention may become apparent to those skilled in the art from a review of the following detailed description, taken in conjunction with the examples and the appended claims. While the invention is susceptible of embodiments in various forms, described hereafter are specific
 25 embodiments of the invention with the understanding that the present disclosure is intended as illustrative, and is not intended to limit the invention to the specific embodiments described herein.

DETAILED DESCRIPTION OF THE INVENTION

30 Surprisingly, we have found that compounds of Formula I:




Formula I

wherein X is O, or S;

Each R_1 is H, alkyl, cycloalkyl, halogenated alkyl, substituted phenyl, or substituted naphthyl;

5 Azabicyclo is



R_0 is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl;


Each R_2 is independently alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl, or R_2 is absent provided that k_2 , k_5 , or k_6 is 0;

10 k_2 is 0 or 1;

k_5 and k_6 are independently 0, 1, or 2;

R_{2-3} is H, alkyl, halogenated alkyl, substituted alkyl, F, Cl, Br, or I;

W^0 is a bicyclic moiety and is



15

W is C(H) where

V---Z---Y is selected from O-C(R_3)=N, O-C(R_5)₂-N(R_4), O-C(R_5)₂-S, O-N=C(R_5), O-C(R_5)(R_8)-O, O-C(R_5)₂-O, C(R_5)₂-O-C(R_5)₂, S-C(R_3)=N, S-C(R_5)₂-N(R_4), S-N=C(R_5), N=C(R_3)-O, N=C(R_3)-S, N=C(R_3)-N(R_4), N(R_4)-N=C(R_5), N(R_4)-C(R_5)₂-O, N(R_4)-C(R_5)₂-S, N(R_4)-C(R_5)₂-N(R_4), C(R_5)₂-O-N(R_4), C(R_5)₂-S-C(R_5)₂, C(R_5)₂-N(R_4)-C(R_5)₂, C(R_5)₂-N(R_4)-O, C(R_5)₂-N(R_4)-S, C(R_5)=N-O, C(R_5)=N-S, C(R_5)=N-N(R_4),

$C(R_5)(R_{17})-C(R_3)(R_{17})-C(R_5)(R_{17})$, or $C(R_5)_2-C(R_3)(R_5)-C(R_5)_2$;

W is N where

V---Z---Y is selected from O-C(R₃)=N, O-C(R₅)₂-N(R₄), O-C(R₅)₂-S,
O-N=C(R₅) O-C(R₅)₂-O, S-C(R₃)=N, S-C(R₅)₂-N(R₄), S-N=C(R₅), N=C(R₃)-O,
5 N=C(R₃)-S, N=C(R₃)-N(R₄), N(R₄)-N=C(R₃), N(R₄)-C(R₅)₂-O, N(R₄)-C(R₅)₂-S,
N(R₄)-C(R₅)₂-N(R₄), C(R₅)₂-O-N(R₄), C(R₅)₂-N(R₄)-O, C(R₅)₂-N(R₄)-S,
C(R₅)=N-O, C(R₅)=N-S, C(R₃)=N-N(R₄), C(R₅)=C(R₃)-O, C(R₅)=C(R₃)-S,
C(R₅)=C(R₅)-N(R₄), C(R₅)=C(R₅)-C(R₅)₂, or $C(R_5)_2-C(R_3)(R_5)-C(R_5)_2$;

W¹, W², W³, and W⁴ are each independently N or C(R₂₁), provided that no
10 more than two of W¹, W², W³, and W⁴ are N and further provided when more than
two of W¹, W², W³, and W⁴ are C(R₂₁) that no more than two R₂₁ are other than H;

J is N(R₂₃), S, or O;

Q is N(R₁₉), O, or S;

Each R₃ is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted
15 alkyl, cycloalkyl, lactam heterocycloalkyl, phenoxy, substituted phenoxy, R₇, R₉,
-N(R₄)-aryl, -N(R₄)-halogenated phenyl, -N(R₄)-halogenated naphthyl,
-O-halogenated phenyl, -O-substituted phenyl, -O-halogenated naphthyl,
-O-substituted naphthyl, -S-halogenated phenyl, -S-substituted phenyl, -S-halogenated
naphthyl, -S-substituted naphthyl, or alkyl substituted on the ω carbon with R₁₅ where
20 said ω carbon is determined by counting the longest carbon chain of the alkyl moiety
with the C-1 carbon being the carbon attached to the bicyclic moiety W⁰ and the ω
carbon being the carbon furthest, e.g., separated by the greatest number of carbon
atoms in the chain, from said C-1 carbon;

Each R₄ is H, or alkyl;

25 Each R₅ is independently H, F, alkyl, substituted alkyl, halogenated alkyl,
alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl,
halogenated alkynyl, cycloalkyl, -C(O)NH₂, -CO₂R₁, or aryl;

R₆ is H, F, Br, I, Cl, -CN, -CF₃, -OR₁₆, -SR₁₆, or -N(R₁₆)₂;

Lower alkyl is both straight- and branched-chain moieties having from 1-4
30 carbon atoms;

Halogenated lower alkyl is an alkyl moiety having from 1-4 carbon atoms and
having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is
the maximum number of carbon atoms in the moiety;

Substituted lower alkyl is an alkyl moiety from 1-4 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R_7 , R_9 , $-OR_{10}$, $-SR_{10}$, $-N(R_{10})_2$, $-C(O)R_{10}$, $-C(O)NR_{10}R_{10}$, $-CN$, $-NR_{10}C(O)R_{10}$, $-S(O)_2NR_{10}R_{10}$, $-NR_{10}S(O)_2R_{10}$, $-NO_2$, phenyl, or substituted
5 phenyl;

Alkyl is both straight- and branched-chain moieties having from 1-6 carbon atoms;

Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to $(2n+1)$ substituent(s) independently selected from F, Cl, Br, or I where n is the
10 maximum number of carbon atoms in the moiety;

Substituted alkyl is an alkyl moiety from 1-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R_7 , R_9 , $-OR_{10}$, $-SR_{10}$, $-NR_{10}R_{10}$, $-C(O)R_{10}$, $-C(O)NR_{10}R_{10}$, $-CN$, $-NR_{10}C(O)R_{10}$, $-S(O)_2NR_{10}R_{10}$, $-NR_{10}S(O)_2R_{10}$, $-NO_2$, phenyl, or substituted
15 phenyl;

Alkenyl is straight- and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond;

Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to $(2n-1)$ substituent(s) independently selected from F, Cl, Br, or I
20 where n is the maximum number of carbon atoms in the moiety;

Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R_7 , R_9 , $-OR_{10}$, $-SR_{10}$, $-N(R_{10})_2$, $-C(O)R_{10}$, $-C(O)N(R_{10})_2$, $-NR_{10}C(O)R_{10}$, $-S(O)_2N(R_{10})_2$, $-NR_{10}S(O)_2R_{10}$, $-CN$, phenyl, or
25 substituted phenyl;

Alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;

Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to $(2n-3)$ substituent(s) independently selected from F, Cl, Br, or I
30 where n is the maximum number of carbon atoms in the moiety;

Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R_7 , R_9 , $-OR_{10}$, $-SR_{10}$, $-N(R_{10})_2$, $-C(O)R_{10}$,

-C(O)N(R₁₀)₂, -NR₁₀C(O)R₁₀, -S(O)₂N(R₁₀)₂, -NR₁₀S(O)₂R₁₀, -CN, phenyl, or substituted phenyl;

Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms;

Lower cycloalkyl is a cyclic alkyl moiety having from 3-4 carbon atoms;

5 Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from F, or Cl;

Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from -OR₁₀, -SR₁₀, -N(R₁₀)₂, -C(O)R₁₀, -CN, -C(O)N(R₁₀)₂,
10 -NR₁₀C(O)R₁₀, -S(O)₂N(R₁₀)₂, -NR₁₀S(O)₂R₁₀, -NO₂, phenyl, or substituted phenyl;

Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R₁₉)-, or -O-;

Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R₁₉)-, or -O-, and having 1-4 substituents
15 independently selected from F, or Cl;

Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R₁₉)-, or -O- and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R₇, R₉, -OR₁₀, -SR₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀, -NO₂,
20 -S(O)₂NR₁₀R₁₀, -NR₁₀S(O)₂R₁₀, phenyl, or phenyl having 1 substituent selected from R₂₀ and further having 0-3 substituents independently selected from F, Cl, Br, or I;

Lactam heterocycloalkyl is a cyclic moiety having from 4-7 atoms with one atom being only nitrogen with the bond to the lactam heterocycloalkyl thru said atom being only nitrogen and having a =O on a carbon adjacent to said nitrogen, and having
25 up to 1 additional ring atom being oxygen, sulfur, or nitrogen and further having 0-2 substituents selected from F, Cl, Br, I, or R₁₄ where valency allows;


Substituted phenoxy is a phenoxy either having 1-3 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R₁₂ and 0-2 substituents independently selected from F, Cl, Br, or I;

30 Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;


Substituted phenyl is a phenyl either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R₁₂ and 0-3 substituents independently selected from F, Cl, Br, or I;

Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R_{12} and 0-3 substituents independently selected from F, Cl, Br, or I, where the substitution can be independently on either only one ring or both rings of said naphthalene moiety;


R_7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of -O-, =N-, -N(R_{19})-, and -S-, and having 0-1 substituent selected from R_{20} and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R_7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula



wherein A_1 is O, S, or NR_{19} ,



wherein A is CR_{18} or N, A_2 and A_3 are independently selected from CR_{18} , $C(R_{18})_2$, O, S, N, or NR_{19} , provided that both A_2 and A_3 are not simultaneously O, simultaneously S, or simultaneously O and S, or



wherein A_2 and A_3 are independently selected from CR_{18} , $C(R_{18})_2$, O, S, N, or NR_{19} , and A is CR_{18} or N, each 9-membered fused-ring moiety having 0-1 substituent selected from R_{20} and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;

Each R_8 is independently F, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, cycloalkyl, $-C(O)NH_2$, $-CO_2R_1$, or aryl;

R₉ is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R₂₀ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R₉ is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R₂₀ and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond directly or indirectly attached to the core molecule where valency allows;

Each R₁₀ is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R₁₃, cycloalkyl substituted with 1 substituent selected from R₁₃, heterocycloalkyl substituted with 1 substituent selected from R₁₃, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;

Each R₁₁ is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;

R₁₂ is -OR₁₁, -SR₁₁, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NR₁₁R₁₁, -C(O)R₁₁, -NO₂, -C(O)NR₁₁R₁₁, -CN, -NR₁₁C(O)R₁₁, -S(O)₂NR₁₁R₁₁, or -NR₁₁S(O)₂R₁₁;

R₁₃ is -OR₁₁, -SR₁₁, -N(R₁₁)₂, -C(O)R₁₁, -C(O)NR₁₁R₁₁, -CN, -CF₃, -NR₁₁C(O)R₁₁, -S(O)₂N(R₁₁)₂, -NR₁₁S(O)₂R₁₁, or -NO₂;

R₁₄ is alkyl, substituted alkyl, halogenated alkyl, -OR₁₁, -CN, -NO₂, -NR₁₀R₁₀;

R₁₅ is aryl, R₇, or R₉;

R₁₆ is H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, substituted phenyl, or substituted naphthyl;

One of R₁₇ is H, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, -CN, F, Br, Cl, I, -OR₁, -C(O)NH₂, -NHR₁, -SR₁, -CO₂R₁, aryl, R₇, or R₉, and each of the other two R₁₇ is independently alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, -CN, F, Br, Cl, I, -OR₁, -C(O)NH₂, -NHR₁, -SR₁, -CO₂R₁, aryl, R₇, or R₉;

Each R_{18} is independently selected from H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, $-OR_{11}$, $-SR_{11}$, $-NR_{11}R_{11}$, $-C(O)R_{11}$, $-NO_2$, $-C(O)N(R_{11})_2$, $-CN$, $-NR_{11}C(O)R_{11}$, $-S(O)_2N(R_{11})_2$, F, Cl, Br, or I,
5 $-NR_{11}S(O)_2R_{11}$, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl,
10 substituted heterocycloalkyl, $-OR_{11}$, $-SR_{11}$, $-NR_{11}R_{11}$, $-C(O)R_{11}$, $-NO_2$, $-C(O)NR_{11}R_{11}$, $-CN$, $-NR_{11}C(O)R_{11}$, $-S(O)_2NR_{11}R_{11}$, or $-NR_{11}S(O)_2R_{11}$, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;

R_{19} is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected
15 from R_{20} and further having 0-3 substituents independently selected from F, Cl, Br, or I;

R_{20} is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, $-OR_{11}$, $-SR_{11}$, $-NR_{11}R_{11}$, $-C(O)R_{11}$, $-C(O)NR_{11}R_{11}$, $-CN$, $-NR_{11}C(O)R_{11}$, $-S(O)_2NR_{11}R_{11}$, $-NR_{11}S(O)_2R_{11}$, $-NO_2$, alkyl
20 substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R_{13} , cycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R_{13} , or heterocycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or $-R_{13}$;

R_{21} is H, F, Cl, Br, I, alkyl, substituted alkyl, halogenated alkyl, cycloalkyl,
25 $-CN$, $-NR_{22}R_{22}$, $-OR_{22}$, or $-SR_{22}$;

Each R_{22} is independently H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, substituted cycloalkyl, heterocycloalkyl, or substituted heterocycloalkyl;

R_{23} is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl,
30 substituted heterocycloalkyl, substituted phenyl, naphthyl, substituted naphthyl, R_7 , or R_9 ;

or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof useful to treat any one of or combination of

cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

In another aspect, the invention includes methods of treating a mammal suffering from schizophrenia or psychosis by administering compounds of Formula I in conjunction with antipsychotic drugs. The compounds of Formula I and the antipsychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously the compounds of Formula I and the antipsychotic drugs can be incorporated into a single pharmaceutical composition. Alternatively, two separate compositions, i.e., one containing compounds of Formula I and the other containing antipsychotic drugs, can be administered simultaneously.

The present invention also includes the compounds of the present invention, pharmaceutical compositions containing the active compounds, and methods to treat the identified diseases.

25

Abbreviations which are well known to one of ordinary skill in the art may be used (e.g., "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "h" or "hr" for hour or hours, "min" for minute or minutes, and "rt" for room temperature).

All temperatures are in degrees Centigrade.

Room temperature is within the range of 15-25 degrees Celsius.

AChR refers to acetylcholine receptor.

nAChR refers to nicotinic acetylcholine receptor.

Pre-senile dementia is also known as mild cognitive impairment.

SHT₃R refers to the serotonin-type 3 receptor.

α -btx refers to α -bungarotoxin.

FLIPR refers to a device marketed by Molecular Devices, Inc. designed to precisely measure cellular fluorescence in a high throughput whole-cell assay.

5 (Schroeder et. al., *J. Biomolecular Screening*, 1(2), p 75-80, 1996).

TLC refers to thin-layer chromatography.

HPLC refers to high pressure liquid chromatography.

MeOH refers to methanol.

EtOH refers to ethanol.

10 IPA refers to isopropyl alcohol.

THF refers to tetrahydrofuran.

DMSO refers to dimethylsulfoxide.

DMF refers to N,N-dimethylformamide.

EtOAc refers to ethyl acetate.

15 TMS refers to tetramethylsilane.

TEA refers to triethylamine.

DIEA refers to N,N-diisopropylethylamine.

MLA refers to methyllycaconitine.

Ether refers to diethyl ether.

20 HATU refers to O-(7-azabenzotriazol-1-yl)-N,N,N', N'-tetramethyluronium hexafluorophosphate.

CDI refers to carbonyl diimidazole.

NMO refers to N-methylmorpholine-N-oxide.

TPAP refers to tetrapropylammonium perruthenate.

25 Na₂SO₄ refers to sodium sulfate.

K₂CO₃ refers to potassium carbonate.

MgSO₄ refers to magnesium sulfate.

When Na₂SO₄, K₂CO₃, or MgSO₄ is used as a drying agent, it is anhydrous.

Halogen is F, Cl, Br, or I.

30 The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C_{i-j} indicates a moiety of the integer 'i' to the

integer "j" carbon atoms, inclusive. Thus, for example, C₁₋₆ alkyl refers to alkyl of one to six carbon atoms.

Non-inclusive examples of heteroaryl compounds that fall within the definition of R₇ and R₉ include, but are not limited to, thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, isoquinolinyl, cinnolinyl, indazolyl, indoliziny, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, quinazolinyl, quinoxalinyl, naphthridinyl, and furopyridinyl.

Non-inclusive examples of heterocycloalkyl include, but are not limited to, tetrahydrofurano, tetrahydropyrano, morpholino, pyrrolidino, piperidino, piperazine, azetidino, azetidinono, oxindolo, dihydroimidazolo, and pyrrolidinono

Some of the amines described herein require the use of an amine-protecting group to ensure functionalization of the desired nitrogen. One of ordinary skill in the art would appreciate where, within the synthetic scheme to use said protecting group. Amino protecting group includes, but is not limited to, carbobenzyloxy (CBz), *tert* butoxy carbonyl (BOC) and the like. Examples of other suitable amino protecting groups are known to person skilled in the art and can be found in "Protective Groups in Organic synthesis," 3rd Edition, authored by Theodora Greene and Peter Wuts.

ω carbon with R₁₅ where said ω carbon is determined by counting the longest carbon chain of the alkyl moiety with the C-1 carbon being the carbon attached to the bicyclic moiety W⁰ and the ω carbon being the carbon furthest, e.g., separated by the greatest number of carbon atoms in the chain, from said C-1 carbon:

The core molecule is [Azabicyclic-N-(R₁)-C(=X)-]. The bond to the core molecule is between W⁰ and the C(=X) of the core molecule. Therefore, when determining the ω carbon, the C-1 carbon will be the carbon attached, as valency allows, to the W⁰ moiety and the ω carbon will be the carbon furthest from said C-1 carbon.

Mammal denotes human and other mammals.

Brine refers to an aqueous saturated sodium chloride solution.

Equ means molar equivalents.

IR refers to infrared spectroscopy.

Lv refers to leaving groups within a molecule, including Cl, OH, or mixed anhydride.

NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm (δ) downfield from TMS.

5 MS refers to mass spectrometry expressed as m/e or mass/charge unit. HRMS refers to high resolution mass spectrometry expressed as m/e or mass/charge unit. $M+H^+$ refers to the positive ion of a parent plus a hydrogen atom. $M-H^-$ refers to the negative ion of a parent minus a hydrogen atom. $M+Na^+$ refers to the positive ion of a parent plus a sodium atom. $M+K^+$ refers to the positive ion of a parent plus a
10 potassium atom. EI refers to electron impact. ESI refers to electrospray ionization. CI refers to chemical ionization. FAB refers to fast atom bombardment.

Compounds of the present invention may be in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and
15 organic bases, and salts prepared from inorganic acids, and organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, ferric, ferrous, lithium, magnesium, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring
20 substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N, N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine,
25 purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like. Salts derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, phosphorous acid and the like. Salts derived from pharmaceutically acceptable organic non-toxic acids include salts of C_{1-6} alkyl carboxylic acids, di-carboxylic acids, and tri-carboxylic acids such as
30 acetic acid, propionic acid, fumaric acid, succinic acid, tartaric acid, maleic acid, adipic acid, and citric acid, and aryl and alkyl sulfonic acids such as toluene sulfonic acids and the like.

By the term "effective amount" of a compound as provided herein is meant a nontoxic but sufficient amount of the compound(s) to provide the desired effect. As pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound(s) used, the mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount." However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation.

The compounds of Formula I have optically active center(s) on the Azabicyclo moiety. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required. This invention involves racemic mixtures and compositions of varying degrees of stereochemical purities. It is preferred to carry out stereoselective syntheses and/or to subject the reaction product to appropriate purification steps so as to produce substantially optically pure materials. Suitable stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions.

The amount of therapeutically effective compound(s) that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound(s) employed, and thus may vary widely. The compositions contain well know carriers and excipients in addition to a therapeutically effective amount of compounds of Formula I. The pharmaceutical compositions may contain active ingredient in the range of about 0.001 to 100 mg/kg/day for an adult, preferably in the range of about 0.1 to 50 mg/kg/day for an adult. A total daily dose of about 1 to 1000 mg of active ingredient may be appropriate for an adult. The daily dose can be administered in one to four doses per day.

In addition to the compound(s) of Formula I, the composition for therapeutic use may also comprise one or more non-toxic, pharmaceutically acceptable carrier materials or excipients. The term "carrier" material or "excipient" herein means any substance, not itself a therapeutic agent, used as a carrier and/or diluent and/or

adjuvant, or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition into a discrete article such as a capsule or tablet suitable for oral administration. Excipients can include, by way of
5 illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition. Acceptable excipients include lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc,
10 stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropyl-
15 methyl cellulose, or other methods known to those skilled in the art. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. If desired, other active ingredients may be included in the composition.

In addition to the oral dosing, noted above, the compositions of the present
20 invention may be administered by any suitable route, in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compositions may, for example, be administered parenterally, e.g., intravascularly, intraperitoneally, subcutaneously, or intramuscularly. For parenteral administration, saline solution, dextrose solution, or water may be used as a suitable
25 carrier. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol,
30 EtOH, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

The serotonin type 3 receptor (5HT₃R) is a member of a superfamily of ligand-gated ion channels, which includes the muscle and neuronal nAChR, the glycine receptor, and the γ -aminobutyric acid type A receptor. Like the other members of this receptor superfamily, the 5HT₃R exhibits a large degree of sequence homology with α 7 nAChR but functionally the two ligand-gated ion channels are very different. For example, α 7 nAChR is rapidly inactivated, is highly permeable to calcium and is activated by acetylcholine and nicotine. On the other hand, 5HT₃R is inactivated slowly, is relatively impermeable to calcium and is activated by serotonin. These experiments suggest that the α 7 nAChR and 5HT₃R proteins have some degree of homology, but function very differently. Indeed the pharmacology of the channels is very different. For example, Ondansetron, a highly selective 5HT₃R antagonist, has little activity at the α 7 nAChR. The converse is also true. For example, GTS-21, a highly selective α 7 nAChR agonist, has little activity at the 5HT₃R.

α 7 nAChR is a ligand-gated Ca⁺⁺ channel formed by a homopentamer of α 7 subunits. Previous studies have established that α -bungarotoxin (α -btx) binds selectively to this homopentameric, α 7 nAChR subtype, and that α 7 nAChR has a high affinity binding site for both α -btx and methyllycaconitine (MLA). α 7 nAChR is expressed at high levels in the hippocampus, ventral tegmental area and ascending cholinergic projections from nucleus basalis to thalamocortical areas. α 7 nAChR agonists increase neurotransmitter release, and increase cognition, arousal, attention, learning and memory.

Data from human and animal pharmacological studies establish that nicotinic cholinergic neuronal pathways control many important aspects of cognitive function including attention, learning and memory (Levin, E.D., *Psychopharmacology*, 108:417-31, 1992; Levin, E.D. and Simon B.B., *Psychopharmacology*, 138:217-30, 1998). For example, it is well known that nicotine increases cognition and attention in humans. ABT-418, a compound that activates α 4 β 2 and α 7 nAChR, improves cognition and attention in clinical trials of Alzheimer's disease and attention-deficit disorders (Potter, A. et. al., *Psychopharmacology (Berl.)*, 142(4):334-42, Mar. 1999; Wilens, T. E. et. al., *Am. J. Psychiatry*, 156(12):1931-7, Dec. 1999). It is also clear that nicotine and selective but weak α 7 nAChR agonists increase cognition and attention in rodents and non-human primates.

Schizophrenia is a complex multifactorial illness caused by genetic and non-genetic risk factors that produce a constellation of positive and negative symptoms. The positive symptoms include delusions and hallucinations and the negative symptoms include deficits in affect, attention, cognition and information processing.

5 No single biological element has emerged as a dominant pathogenic factor in this disease. Indeed, it is likely that schizophrenia is a syndrome that is produced by the combination of many low penetrance risk factors. Pharmacological studies established that dopamine receptor antagonists are efficacious in treating the overt psychotic features (positive symptoms) of schizophrenia such as hallucinations and

10 delusions. Clozapine, an "atypical" antipsychotic drug, is novel because it is effective in treating both the positive and some of the negative symptoms of this disease. Clozapine's utility as a drug is greatly limited because continued use leads to an increased risk of agranulocytosis and seizure. No other antipsychotic drug is effective in treating the negative symptoms of schizophrenia. This is significant because the

15 restoration of cognitive functioning is the best predictor of a successful clinical and functional outcome of schizophrenic patients (Green, M.F., *Am J Psychiatry*, 153:321-30, 1996). By extension, it is clear that better drugs are needed to treat the cognitive disorders of schizophrenia in order to restore a better state of mental health to patients with this disorder.

20 One aspect of the cognitive deficit of schizophrenia can be measured by using the auditory event-related potential (P50) test of sensory gating. In this test, electroencephalographic (EEG) recordings of neuronal activity of the hippocampus are used to measure the subject's response to a series of auditory "clicks" (Adler, L.E. et. al., *Biol. Psychiatry*, 46:8-18, 1999). Normal individuals respond to the first click

25 with greater degree than to the second click. In general, schizophrenics and schizotypal patients respond to both clicks nearly the same (Cullum, C.M. et. al., *Schizophr. Res.*, 10:131-41, 1993). These data reflect a schizophrenic's inability to "filter" or ignore unimportant information. The sensory gating deficit appears to be one of the key pathological features of this disease (Cadenhead, K.S. et. al., *Am. J.*

30 *Psychiatry*, 157:55-9, 2000). Multiple studies show that nicotine normalizes the sensory deficit of schizophrenia (Adler, L.E. et. al., *Am. J. Psychiatry*, 150:1856-61, 1993). Pharmacological studies indicate that nicotine's effect on sensory gating is via the $\alpha 7$ nAChR (Adler, L.E. et. al., *Schizophr. Bull.*, 24:189-202, 1998). Indeed, the

biochemical data indicate that schizophrenics have 50% fewer of $\alpha 7$ nAChR receptors in the hippocampus, thus giving a rationale to partial loss of $\alpha 7$ nAChR functionality (Freedman, R. et. al., *Biol. Psychiatry*, 38:22-33, 1995). Interestingly, genetic data indicate that a polymorphism in the promoter region of the $\alpha 7$ nAChR gene is strongly associated with the sensory gating deficit in schizophrenia (Freedman, R. et. al., *Proc. Nat'l Acad. Sci. USA*, 94(2):587-92, 1997; Myles-Worsley, M. et. al., *Am. J. Med. Genet*, 88(5):544-50, 1999). To date, no mutation in the coding region of the $\alpha 7$ nAChR has been identified. Thus, schizophrenics express the same $\alpha 7$ nAChR as non-schizophrenics.

10 Selective $\alpha 7$ nAChR agonists may be found using a functional assay on FLIPR (see WO 00/73431 A2). FLIPR is designed to read the fluorescent signal from each well of a 96 or 384 well plate as fast as twice a second for up to 30 minutes. This assay may be used to accurately measure the functional pharmacology of $\alpha 7$ nAChR and 5HT₃R. To conduct such an assay, one uses cell lines that expressed functional forms of the $\alpha 7$ nAChR using the $\alpha 7/5$ -HT₃ channel as the drug target and cell lines
15 that expressed functional 5HT₃R. In both cases, the ligand-gated ion channel was expressed in SH-EP1 cells. Both ion channels can produce robust signal in the FLIPR assay.

The compounds of the present invention are $\alpha 7$ nAChR agonists and may be
20 used to treat a wide variety of diseases. For example, they may be used in treating schizophrenia, or psychosis.

Schizophrenia is a disease having multiple aspects. Currently available drugs are generally aimed at controlling the positive aspects of schizophrenia, such as delusions. One drug, Clozapine, is aimed at a broader spectrum of symptoms
25 associated with schizophrenia. This drug has many side effects and is thus not suitable for many patients. Thus, there is a need for a drug to treat the cognitive and attention deficits associated with schizophrenia. Similarly, there is a need for a drug to treat the cognitive and attention deficits associated with schizoaffective disorders, or similar symptoms found in the relatives of schizophrenic patients.

30 Psychosis is a mental disorder characterized by gross impairment in the patient's perception of reality. The patient may suffer from delusions, and hallucinations, and may be incoherent in speech. His behavior may be agitated and is often incomprehensible to those around him. In the past, the term psychosis has been

applied to many conditions that do not meet the stricter definition given above. For example, mood disorders were named as psychoses.

There are a variety of antipsychotic drugs. The conventional antipsychotic drugs include Chlorpromazine, Fluphenazine, Haloperidol, Loxapine, Mesoridazine, Molindone, Perphenazine, Pimozide, Thioridazine, Thiothixene, and Trifluoperazine. These drugs all have an affinity for the dopamine 2 receptor.

These conventional antipsychotic drugs have several side effects, including sedation, weight gain, tremors, elevated prolactin levels, akathisia (motor restlessness), dystonia and muscle stiffness. These drugs may also cause tardive dyskinesia. Unfortunately, only about 70% of patients with schizophrenia respond to conventional antipsychotic drugs. For these patients, atypical antipsychotic drugs are available.

Atypical antipsychotic drugs generally are able to alleviate positive symptoms of psychosis while also improving negative symptoms of the psychosis to a greater degree than conventional antipsychotics. These drugs may improve neurocognitive deficits. Extrapyramidal (motor) side effects are not as likely to occur with the atypical antipsychotic drugs, and thus, these atypical antipsychotic drugs have a lower risk of producing tardive dyskinesia. Finally these atypical antipsychotic drugs cause little or no elevation of prolactin. Unfortunately, these drugs are not free of side effects. Although these drugs each produce different side effects, as a group the side effects include: agranulocytosis; increased risk of seizures, weight gain, somnolence, dizziness, tachycardia, decreased ejaculatory volume, and mild prolongation of QTc interval.

In a combination therapy to treat multiple symptoms of diseases such as schizophrenia, the compounds of Formula I and the anti-psychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously the compounds of Formula I and the anti-psychotic drugs can be incorporated into a single pharmaceutical composition, e.g., a pharmaceutical combination therapy composition. Alternatively, two separate compositions, i.e., one containing compounds of Formula I and the other containing anti-psychotic drugs, can be administered simultaneously. Examples of anti-psychotic drugs, in addition to those listed above, include, but are not limited to, Thorazine, Mellaril, Trilafon, Navane, Stelazine, Permitil, Prolixin, Risperdal, Zyprexa, Seroquel, ZELDOX,

Acetophenazine, Carphenazine, Chlorprothixene, Droperidol, Loxapine, Mesoridazine, Molindone, Ondansetron, Pimozide, Prochlorperazine, and Promazine.

A pharmaceutical combination therapy composition can include therapeutically effective amounts of the compounds of Formula I, noted above, and a therapeutically effective amount of anti-psychotic drugs. These compositions may be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated elixirs or solutions for convenient oral administration or administered by intramuscular intravenous routes. The compounds can be administered rectally, topically, orally, sublingually, or parenterally and maybe formulated as sustained relief dosage forms and the like.

When separately administered, therapeutically effective amounts of compositions containing compounds of Formula I and anti-psychotic drugs are administered on a different schedule. One may be administered before the other as long as the time between the two administrations falls within a therapeutically effective interval. A therapeutically effective interval is a period of time beginning when one of either (a) the compounds of Formula I, or (b) the anti-psychotic drugs is administered to a human and ending at the limit of the beneficial effect in the treatment of schizophrenia or psychosis of the combination of (a) and (b). The methods of administration of the compounds of Formula I and the anti-psychotic drugs may vary. Thus, either agent or both agents may be administered rectally, topically, orally, sublingually, or parenterally.

As discussed, the compounds of the present invention are $\alpha 7$ nAChR agonists. Therefore, as another aspect of the present invention, the compounds of the present invention may be used to treat a variety of diseases including cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (also known as mild cognitive impairment), and senile dementia.

Alzheimer's disease has many aspects, including cognitive and attention deficits. Currently, these deficits are treated with cholinesterase inhibitors. These inhibitors slow the break down of acetylcholine, and thereby provide a general nonspecific increase in the activity of the cholinergic nervous system. Since the drugs are nonspecific, they have a wide variety of side effects. Thus, there is a need for a

drug that stimulates a portion of the cholinergic pathways and thereby provides improvement in the cognitive and attention deficits associated with Alzheimer's disease without the side effects created by nonspecific stimulation of the cholinergic pathways.

5 Neurodegeneration is a common problem associated with diseases such as Alzheimer's disease. While the current drugs treat some of the symptoms of this disease, they do not control the underlying pathology of the disease. Accordingly, it would be desirable to provide a drug that can slow the progress of Alzheimer's disease.

10 Pre-senile dementia (mild cognitive impairment) concerns memory impairment rather than attention deficit problems and otherwise unimpaired cognitive functioning. Mild cognitive impairment is distinguished from senile dementia in that mild cognitive impairment involves a more persistent and troublesome problem of memory loss for the age of the patient. There currently is no medication specifically
15 identified for treatment of mild cognitive impairment, due somewhat to the newness of identifying the disease. Therefore, there is a need for a drug to treat the memory problems associated with mild cognitive impairment.

 Senile dementia is not a single disease state. However, the conditions classified under this name frequently include cognitive and attention deficits.
20 Generally, these deficits are not treated. Accordingly, there is a need for a drug that provides improvement in the cognitive and attention deficits associated with senile dementia.

 As discussed, the compounds of the present invention are $\alpha 7$ nAChR agonists.
25 Therefore, yet other diseases to be treated with compounds of the present invention include treating the cognitive and attention deficits as well as the neurodegeneration associated with any one or more or combination of the following: attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic
30 lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease,

dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

5 Attention deficit disorder is generally treated with methylphenidate, an amphetamine-like molecule that has some potential for abuse. Accordingly, it would be desirable to provide a drug that treats attention deficit disorder while having fewer side effects than the currently used drug.

10 Attention deficit hyperactivity disorder, otherwise known as ADHD, is a neurobehavioral disorder affecting 3-5% of all American children. ADHD concerns cognitive alone or both cognitive and behavioral actions by interfering with a person's ability to stay on a task and to exercise age-appropriate inhibition. Several types of ADHD exist: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. Treatment may include medications such as methylphenidate, dextroamphetamine, or pemoline, which act to decrease
15 impulsivity and hyperactivity and to increase attention. No "cure" for ADHD currently exists. Children with the disorder seldom outgrow it; therefore, there is a need for appropriate medicaments.

20 Depression is a mood disorder of varying lengths of normally several months to more than two years and of varying degrees of feelings involving sadness, despair, and discouragement. The heterocyclic antidepressants (HCA's) are currently the largest class of antidepressants, but monoamine oxidase inhibitors (MAOI's) are used in particular types of depression. Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects from
25 HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Therefore, agents with fewer side effects would be useful.

 Anxiety disorders (disorders with prominent anxiety or phobic avoidance), represent an area of unmet medical needs in the treatment of psychiatric illness. See
30 Diagnostic & Statistical Manual of Mental Disorders, IV (1994), pp 393-394, for various disease forms of anxiety.

 General anxiety disorder (GAD) occurs when a person worries about things such as family, health, or work when there is no reason to worry and is unable not to

worry. About 3 to 4% of the U.S. population has GAD during the course of a year. GAD most often strikes people in childhood or adolescence, but can begin in adulthood, too. It affects women more often than men. Currently, treatment involves cognitive-behavioral therapy, relaxation techniques, and biofeedback to control
5 muscle tension and medications such as benzodiazepines, imipramine, and buspirone. These drugs are effective but all have side-effect liabilities. Therefore, there is a need of a pharmaceutical agent to address the symptoms with fewer side effects.

Anxiety also includes post-traumatic stress disorder (PTSD), which is a form of anxiety triggered by memories of a traumatic event that directly affected the patient
10 or that the patient may have witnessed. The disorder commonly affects survivors of traumatic events including sexual assault, physical assault, war, torture, natural disasters, an automobile accident, an airplane crash, a hostage situation, or a death camp. The affliction also can affect rescue workers at an airplane crash or a mass shooting, someone who witnessed a tragic accident or someone who has unexpectedly
15 lost a loved one. Treatment for PTSD includes cognitive-behavioral therapy, group psychotherapy, and medications such as Clonazepam, Lorazepam and selective serotonin-reuptake inhibitors such as Fluoxetine, Sertraline, Paroxetine, Citalopram and Fluvoxamine. These medications help control anxiety as well as depression. Various forms of exposure therapy (such as systemic desensitization and imaginal
20 flooding) have all been used with PTSD patients. Exposure treatment for PTSD involves repeated reliving of the trauma, under controlled conditions, with the aim of facilitating the processing of the trauma. Therefore, there is a need for better pharmaceutical agents to treat post traumatic stress disorder.

Mood and affective disorders fall within a large group of diseases, including
25 monopolar depression and bi-polar mood disorder. These diseases are treated with three major classes of compounds. The first group is the heterocyclic antidepressant (HCA's). This group includes the well-known tricyclic antidepressants. The second group of compounds used to treat mood disorders is the monoamine oxidase inhibitors (MAOI's) that are used in particular types of diseases. The third drug is lithium.
30 Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects of HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Benign side effects from the use of lithium include, but are not

limited to, weight gain, nausea, diarrhea, polyuria, polydipsia, and tremor. Toxic side effects from lithium can include persistent headache, mental confusion, and may reach seizures and cardiac arrhythmias. Therefore, agents with less side effects or interactions with food or other medications would be useful.

5 Borderline personality disorder, although not as well known as bipolar disorder, is more common. People having borderline personality disorder suffer from a disorder of emotion regulation. Pharmaceutical agents are used to treat specific symptoms, such as depression or thinking distortions.

10 Acquired immune deficiency syndrome (AIDS) results from an infection with the human immunodeficiency virus (HIV). This virus attacks selected cells and impairs the proper function of the immune, nervous, and other systems. HIV infection can cause other problems such as, but not limited to, difficulties in thinking, otherwise known as AIDS dementia complex. Therefore, there is a need to drugs to relieve the confusion and mental decline of persons with AIDS.

15 Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, belongs to a class of disorders known as motor neuron diseases wherein specific nerve cells in the brain and spinal cord gradually degenerate to negatively affect the control of voluntary movement. Currently, there is no cure for amyotrophic lateral sclerosis although patients may receive treatment from some of their symptoms and although
20 Riluzole has been shown to prolong the survival of patients. Therefore, there is a need for a pharmaceutical agent to treat this disease.

 Traumatic brain injury occurs when the brain is damaged from a sudden physical assault on the head. Symptoms of the traumatic brain injury include confusion and other cognitive problems. Therefore, there is a need to address the
25 symptoms of confusion and other cognitive problems.

 Brain tumors are abnormal growths of tissue found inside of the skull. Symptoms of brain tumors include behavioral and cognitive problems. Surgery, radiation, and chemotherapy are used to treat the tumor, but other agents are necessary to address associated symptoms. Therefore, there is a need to address the symptoms
30 of behavioral and cognitive problems.

 Persons with Down's syndrome have in all or at least some of their cells an extra, critical portion of the number 21 chromosome. Adults who have Down's syndrome are known to be at risk for Alzheimer-type dementia. Currently, there is no

proven treatment for Down's syndrome. Therefore, there is a need to address the dementia associated with Down's syndrome.

Genetically programmed degeneration of neurons in certain areas of the brain cause Huntington's disease. Early symptoms of Huntington's disease include mood swings, or trouble learning new things or remembering a fact. Most drugs used to
5 treat the symptoms of Huntington's disease have side effects such as fatigue, restlessness, or hyperexcitability. Currently, there is no treatment to stop or reverse the progression of Huntington's disease. Therefore, there is a need of a pharmaceutical agent to address the symptoms with fewer side effects.

10 Dementia with Lewy Bodies is a neurodegenerative disorder involving abnormal structures known as Lewy bodies found in certain areas of the brain. Symptoms of dementia with Lewy bodies include, but are not limited to, fluctuating cognitive impairment with episodic delirium. Currently, treatment concerns addressing the parkinsonian and psychiatric symptoms. However, medicine to control
15 tremors or loss of muscle movement may actually accentuate the underlying disease of dementia with Lewy bodies. Therefore, there is a need of a pharmaceutical agent to treat dementia with Lewy bodies.

Parkinson's disease is a neurological disorder characterized by tremor, hypokinesia, and muscular rigidity. Currently, there is no treatment to stop the
20 progression of the disease. Therefore, there is a need of a pharmaceutical agent to address Parkinson's.

Tardive dyskinesia is associated with the use of conventional antipsychotic drugs. This disease is characterized by involuntary movements most often manifested by puckering of the lips and tongue and/or writhing of the arms or legs. The incidence
25 of tardive dyskinesia is about 5% per year of drug exposure among patients taking conventional antipsychotic drugs. In about 2% of persons with the disease, tardive dyskinesia is severely disfiguring. Currently, there is no generalized treatment for tardive dyskinesia. Furthermore, the removal of the effect-causing drugs is not always an option due to underlying problems. Therefore, there is a need for a pharmaceutical
30 agent to address the symptoms of tardive dyskinesia.

Pick's disease results from a slowly progressive deterioration of social skills and changes in personality with the resulting symptoms being impairment of intellect, memory, and language. Common symptoms include memory loss, lack of

spontaneity, difficulty in thinking or concentrating, and speech disturbances.

Currently, there is no specific treatment or cure for Pick's disease but some symptoms can be treated with cholinergic and serotonin-boosting antidepressants. In addition, antipsychotic medications may alleviate symptoms in FTD patients who are
5 experiencing delusions or hallucinations. Therefore, there is a need for a pharmaceutical agent to treat the progressive deterioration of social skills and changes in personality and to address the symptoms with fewer side effects.

Dysregulation of food intake associated with eating disease, including bulimia nervosa and anorexia nervosa, involve neurophysiological pathways. Anorexia
10 nervosa is hard to treat due to patients not entering or remaining in after entering programs. Currently, there is no effective treatment for persons suffering from severe anorexia nervosa. Cognitive behavioral therapy has helped patients suffering from bulimia nervosa; however, the response rate is only about 50% and current treatment does not adequately address emotional regulation. Therefore, there is a need for
15 pharmaceutical agents to address neurophysiological problems underlying diseases of dysregulation of food intake.

Cigarette smoking has been recognized as a major public health problem for a long time. However, in spite of the public awareness of health hazard, the smoking habit remains extraordinarily persistent and difficult to break. There are many
20 treatment methods available, and yet people continue to smoke. Administration of nicotine transdermally, or in a chewing gum base is common treatments. However, nicotine has a large number of actions in the body, and thus can have many side effects. It is clear that there is both a need and a demand of long standing for a convenient and relatively easy method for aiding smokers in reducing or eliminating
25 cigarette consumption. A drug that could selectively stimulate only certain of the nicotinic receptors would be useful in smoke cessation programs.

Smoke cessation programs may involve oral dosing of the drug of choice. The drug may be in the form of tablets. However, it is preferred to administer the daily dose over the waking hours, by administration of a series of incremental doses during
30 the day. The preferred method of such administration is a slowly dissolving lozenge, troche, or chewing gum, in which the drug is dispersed. Another drug in treating nicotine addiction is Zyban. This is not a nicotine replacement, as are the gum and patch. Rather, this works on other areas of the brain, and its effectiveness is to help

control nicotine craving or thoughts about cigarette use in people trying to quit.

Zyban is not very effective and effective drugs are needed to assist smokers in their desire to stop smoking. These drugs may be administered transdermally through the use of skin patches. In certain cases, the drugs may be administered by subcutaneous injection, especially if sustained release formulations are used.

Drug use and dependence is a complex phenomenon, which cannot be encapsulated within a single definition. Different drugs have different effects, and therefore different types of dependence. Drug dependence has two basic causes, that is, tolerance and physical dependence. Tolerance exists when the user must take progressively larger doses to produce the effect originally achieved with smaller doses. Physical dependence exists when the user has developed a state of physiologic adaptation to a drug, and there is a withdrawal (abstinence) syndrome when the drug is no longer taken. A withdrawal syndrome can occur either when the drug is discontinued or when an antagonist displaces the drug from its binding site on cell receptors, thereby counteracting its effect. Drug dependence does not always require physical dependence.

In addition drug dependence often involves psychological dependence, that is, a feeling of pleasure or satisfaction when taking the drug. These feelings lead the user to repeat the drug experience or to avoid the displeasure of being deprived of the drug. Drugs that produce strong physical dependence, such as nicotine, heroin and alcohol are often abused, and the pattern of dependence is difficult to break. Drugs that produce dependence act on the CNS and generally reduce anxiety and tension; produce elation, euphoria, or other pleasurable mood changes; provide the user feelings of increased mental and physical ability; or alter sensory perception in some pleasurable manner. Among the drugs that are commonly abused are ethyl alcohol, opioids, anxiolytics, hypnotics, cannabis (marijuana), cocaine, amphetamines, and hallucinogens. The current treatment for drug-addicted people often involves a combination of behavioral therapies and medications. Medications, such as methadone or LAAM (levo-alpha-acetyl-methadol), are effective in suppressing the withdrawal symptoms and drug craving associated with narcotic addiction, thus reducing illicit drug use and improving the chances of the individual remaining in treatment. The primary medically assisted withdrawal method for narcotic addiction is to switch the patient to a comparable drug that produces milder withdrawal

symptoms, and then gradually taper off the substitute medication. The medication used most often is methadone, taken orally once a day. Patients are started on the lowest dose that prevents the more severe signs of withdrawal and then the dose is gradually reduced. Substitutes can be used also for withdrawal from sedatives.

5 Patients can be switched to long-acting sedatives, such as diazepam or phenobarbital, which are then gradually reduced.

Gilles de la Tourette's Syndrome is an inherited neurological disorder. The disorder is characterized by uncontrollable vocal sounds called tics and involuntary movements. The symptoms generally manifest in an individual before the person is
10 18 years of age. The movement disorder may begin with simple tics that progress to multiple complex tics, including respiratory and vocal ones. Vocal tics may begin as grunting or barking noises and evolve into compulsive utterances. Coprolalia (involuntary scatologic utterances) occurs in 50% of patients. Severe tics and coprolalia may be physically and socially disabling. Tics tend to be more complex
15 than myoclonus, but less flowing than choreic movements, from which they must be differentiated. The patient may voluntarily suppress them for seconds or minutes.

Currently simple tics are often treated with benzodiazepines. For simple and complex tics, Clonidine may be used. Long-term use of Clonidine does not cause tardive dyskinesia; its limiting adverse effect is hypotension. In more severe cases,
20 antipsychotics, such as Haloperidol may be required, but side effects of dysphoria, parkinsonism, akathisia, and tardive dyskinesia may limit use of such antipsychotics. There is a need for safe and effective methods for treating this syndrome.

Age-related macular degeneration (AMD) is a common eye disease of the macula which is a tiny area in the retina that helps produce sharp, central vision
25 required for "straight ahead" activities that include reading and driving. Persons with AMD lose their clear, central vision. AMD takes two forms: wet and dry. In dry AMD, there is a slow breakdown of light-sensing cells in the macula. There currently is no cure for dry AMD. In wet AMD, new, fragile blood vessels growing beneath the macula as dry AMD worsens and these vessels often leak blood and fluid to cause
30 rapid damage to the macula quickly leading to the loss of central vision. Laser surgery can treat some cases of wet AMD. Therefore, there is a need of a pharmaceutical agent to address AMD.

Glaucoma is within a group of diseases occurs from an increase in intraocular pressure causing pathological changes in the optical disk and negatively affects the field of vision. Medicaments to treat glaucoma either decrease the amount of fluid entering the eye or increase drainage of fluids from the eye in order to decrease
5 intraocular pressure. However, current drugs have drawbacks such as not working over time or causing side effects so the eye-care professional has to either prescribe other drugs or modify the prescription of the drug being used. There is a need for safe and effective methods for treating problems manifesting into glaucoma.

Ischemic periods in glaucoma cause release of excitotoxic amino acids and
10 stimulate inducible form of nitric oxide synthase (iNOS) leading to neurodegeneration. Alpha 7 nicotinic agonists may stimulate the release of inhibitory amino acids such as GABA which will dampen hyperexcitability. Alpha 7 nicotinic agonists are also directly neuroprotective on neuronal cell bodies. Thus alpha 7 nicotinic agonists have the potential to be neuroprotective in glaucoma.

15 Persons afflicted with pain often have what is referred to as the "terrible triad" of suffering from the pain, resulting in sleeplessness and sadness, all of which are hard on the afflicted individual and that individual's family. Pain can manifest itself in various forms, including, but not limited to, headaches of all severity, back pain, neurogenic, and pain from other ailments such as arthritis and cancer from its
20 existence or from therapy to irradiate it. Pain can be either chronic (persistent pain for months or years) or acute (short-lived, immediate pain to inform the person of possible injury and need of treatment). Persons suffering from pain respond differently to individual therapies with varying degrees of success. There is a need for safe and effective methods for treating pain.


25 Finally, the compounds of the present invention may be used in combination therapy with typical and atypical anti-psychotic drugs (also called an anti-psychotic agent). All compounds within the present invention are useful for and may also be used in combination with each other to prepare pharmaceutical compositions. Such combination therapy lowers the effective dose of the anti-psychotic drug and thereby
30 reduces the side effects of the anti-psychotic drugs. Some typical anti-psychotic drugs that may be used in the practice of the invention include Haldol. Some atypical anti-psychotic drugs include Ziprasidone, Olanzapine, Risperidone, and Quetiapine.

Compounds of Formula I can be prepared as shown in Scheme 1. The key step in the preparation of this class of compounds is the coupling of an azabicyclic moiety with the requisite acid chloride ($L_v = Cl$), mixed anhydride (e.g., $L_v =$ diphenyl phosphoryl, bis(2-oxo-3-oxazolidinyl)phosphinyl, or acyloxy of the general formula of

5 O-C(O)- R_{L_v} , where R_{L_v} includes phenyl or t-butyl), or carboxylic acid ($L_v = OH$) in the presence of an activating reagent. Suitable activating reagents are well known in the art, for examples see Kiso, Y., Yajima, H. "Peptides" pp. 39-91, San Diego, CA, Academic Press, (1995), and include, but are not limited to, agents such as carbodiimides, phosphonium and uronium salts (such as HATU).

10

Scheme 1



Generally, for most Azabicyclo moities, the acid is activated using HATU or is converted to the acyl azide by using DPPA. The appropriate amine precursor is added

15 to a solution of the appropriate anhydride or azide to give the desired final compounds. In some cases, the ester (L_v being OMe or OEt) may be reacted directly with the amine precursor in refluxing methanol or ethanol to give the compounds of Formula I.

Preferably, for Azabicyclo V, the acid is converted into a mixed anhydride by


20 treatment with bis (2-oxo-3-oxazolidinyl) phosphinic chloride in the presence of TEA with CH₂Cl₂ or CHCl₃ as the solvent. The resulting anhydride solution is directly reacted with 1-azabicyclo[3.2.1]octan-3-amine added neat or using DMF or aqueous DMF as solvent. In some cases, the ester (L_v being OMe or OEt) may be reacted directly with the amine in refluxing methanol or ethanol to give the compounds of

25 Formula I.

Certain 6-substituted-[2.2.2]-3-amines (Azabicyclo I) are known in the art. The preparation of compounds where R₂ is other than H is described in *Acta Pol. Pharm.* 179-85 (1981). Alternatively, the 6-substituted-[2.2.2]-3-amine can be prepared by reduction of an oxime or an imine of the corresponding 6-substituted-3-


30 quinuclidinone by methods known to one of ordinary skill in the art (see *J. Labelled Compds. Radiopharm.*, 53-60 (1995), *J. Med. Chem.* 988-995, (1998), *Synth.*

Commun. 1895-1911 (1992), *Synth. Commun.* 2009-2015 (1996)). Alternatively, the 6-substituted-[2.2.2]-3-amine can be prepared from a 6-substituted-3-hydroxyquinuclidine by Mitsunobu reaction followed by deprotection as described in *Synth. Commun.* 1895-1911 (1995). Alternatively, the 6-substituted-[2.2.2]-3-amine can be prepared by conversion of a 6-substituted-3-hydroxyquinuclidine into the corresponding mesylate or tosylate, followed by displacement with sodium azide and reduction as described in *J. Med. Chem.* 587-593 (1975).




The oximes can be prepared by treatment of the 3-quinuclidinones with hydroxylamine hydrochloride in the presence of base. The imines can be prepared by treatment of the 3-quinuclidinones with a primary amine under dehydrating conditions. The 3-hydroxyquinuclidines can be prepared by reduction of the 3-quinuclidinones. The 6-substituted-3-quinuclidinones can be prepared by known procedures (see *J. Gen. Chem. Russia* 3791-3795, (1963), *J. Chem. Soc. Perkin Trans. I* 409-420 (1991), *J. Org. Chem.* 3982-3996 (2000)).

One of ordinary skill in the art will recognize that the methods described for the reaction of the unsubstituted 3-amino-1-azabicyclo[2.2.1]heptane (R₂=absent) are equally applicable to substituted compounds (R₂ ≠ H). For where Azabicyclo is II, compounds where R₂ is other than H can be prepared from appropriately substituted nitro alcohols using procedures described in *Tetrahedron* (1997), 53, p. 11121 as shown below. Methods to synthesize nitro alcohols are well known in the art (see *J. Am. Chem. Soc.* (1947), 69, p 2608). The scheme below is a modification of the synthesis of *exo*-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt, described in detail herein, to show how to obtain these amine precursors. The desired salt can be made using standard procedures.




Compounds for Azabicyclo II where R_2 is other than H can also be prepared by modification of intermediates described in the synthesis of *exo*-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt, described in detail herein. For example, Int 6 can be oxidized to the aldehyde and treated with an organometallic reagent to provide Int 20 using procedures described in *Tetrahedron* (1999), 55, p 13899. Int 20 can be converted into the amine using methods described for the synthesis of *exo*-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt. Once the amine is obtained, the desired salt can be made using standard procedures.

The schemes used are for making *exo*-3-amino-1-azabicyclo[2.2.1]heptane. However, the modifications discussed are applicable to make the *endo* isomer also.



There are several methods by which the amine precursor for Azabicyclo III and Azabicyclo IV can be obtained.

N-(2-azabicyclo[2.2.1]hept)-5-amine and 6-amine:



where Lv can be $-\text{CH}_2\text{Ph}$, $-\text{CH}(\text{Me})\text{Ph}$, $-\text{OH}$, $-\text{OMe}$, or $-\text{OCH}_2\text{Ph}$.

The respective amine precursors for Azabicyclo III and Azabicyclo IV can be prepared by reduction of an oxime or an imine of the corresponding *N*-2-azabicyclo[2.2.1]-heptanone by methods known to one skilled in the art (see *J. Labelled Compds. Radiopharm.*, 53-60 (1995), *J. Med. Chem.* 988-995, (1998), *Synth. Commun.* 1895-1911 (1992), *Synth. Commun.* 2009-2015 (1996)). The oximes can be prepared by treatment of the *N*-2-azabicyclo[2.2.1]heptanones with hydroxylamine hydrochloride in the presence of a base. The imines can be prepared by treatment of the *N*-2-azabicyclo[2.2.1]-heptanones with a primary amine under dehydrating conditions. The *N*-2-azabicyclo[2.2.1]heptanones can be prepared by known procedures (see *Tet. Lett.* 1419-1422 (1999), *J. Med. Chem.* 2184-2191 (1992), *J. Med. Chem.* 706-720 (2000), *J. Org. Chem.*, 4602-4616 (1995)).

The *exo*- and *endo*-1-azabicyclo[3.2.1]octan-3-amines are prepared from 1-azabicyclo[3.2.1]octan-3-one (Thill, B. P., Aaron, H. S., *J. Org. Chem.*, 4376-4380 (1968)) according to the general procedure as discussed in Lewin, A.H., et al., *J. Med. Chem.*, 988-995 (1998).



One of ordinary skill in the art will also recognize that the methods described for the reaction of the unsubstituted 1-azabicyclo[3.2.1]octan-3-amine or 1-azabicyclo[3.2.2]nonan-3-amine (R_2 =absent) are equally applicable to substituted compounds (R_2 present). The R_2 substituent may be introduced as known to one skilled in the art through standard alkylation chemistry. Exposure of 1-azabicyclo[3.2.1]octan-3-one or 1-azabicyclo[3.2.2]nonan-3-one to a hindered base such as LDA (lithium diisopropylamide) in a solvent such as THF or ether between

0°C to -78°C followed by the addition of an alkylating agent (R_2Lv , where $Lv = Cl, Br, I, OTs$, etc.) will, after being allowed to warm to about 0°C to rt followed by an aqueous workup, provide the desired compound as a mixture of isomers.

Chromatographic resolution (flash, HPLC, or chiral HPLC) will provided the desired
5 purified alkylated ketones. From there, formation of the oxime and subsequent reduction will provide the desired *endo* or *exo* isomers.


It will be apparent to those skilled in the art that the requisite carboxylic acids can be obtained through synthesis via literature procedures or through the slight modification thereof.

10 Thioamides can be prepared from the requisite thioester by direct displacement of the thioester with an amino precursor of the Azabicyclo, for example, see Scheme 2. The thioester can be prepared as described in *J. Organometallic Chem.*, 95-98 (1987). One of ordinary skill in the art would quickly identify that said compounds could also be prepared directly from the amides exemplified throughout this patent by
15 direct treatment with a reagent such and Lawesson's reagent (see Lawesson et. al. in *Bull. Soc. Chim. Belg.*, 229 (1978)) or P_4S_{10} (see *Chem. Rev.*, 45 (1961)). Alternatively one can react a dithiocarboxylic ester with the corresponding amino-azabicyclo compound to form the same thioamide.

Furthermore, the examples provided are carried out using one amine.
20 However, either amine could be used making non-critical changes but starting with the amine not identified. Therefore, the stereospecificity of the resulting compound is not drawn. But, the scope of this invention includes the four different stereoisomers as described herein as well as racemic mixtures.

25 Preparation of the 2.2.1 Amines:

Synthesis of *exo*-3-amino-1-azabicyclo[2.2.1]heptane
as the bis(hydro para-toluenesulfonate) salt:



Step A. Preparation of 2-(benzoyloxy)-1-nitroethane (Int 1).

Benzoyl chloride (14.9 mL, 128 mmol) is added to a stirred solution of nitroethanol (9.2 mL, 128 mmol) in dry benzene (120 mL). The solution is refluxed for 24 hr and then concentrated *in vacuo*. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (80:20) affords Int 1 as a white solid (68% yield): ^1H NMR (CDCl_3) δ 8.0, 7.6, 7.4, 4.9, 4.8.

Step B. Preparation of ethyl E-4-(benzylamino)-2-butenate (Int 2).

Ethyl E-4-bromo-2-butenate (10 mL, 56 mmol, tech grade) is added to a stirred solution of benzylamine (16 mL, 146 mmol) in CH_2Cl_2 (200 mL) at rt. The reaction mixture stirs for 15 min, and is diluted with ether (1 L). The mixture is washed with saturated aqueous NaHCO_3 solution (3x) and water, dried over Na_2SO_4 , filtered and concentrated *in vacuo*. The residue is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (70:30) affords Int 2 as a clear oil (62% yield): ^1H NMR (CDCl_3) δ 7.4-7.2, 7.0, 6.0, 4.2, 3.8, 3.4, 2.1-1.8, 1.3.

Step C. Preparation of *trans*-4-nitro-1-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 3).

A solution of Int 1 (6.81 g, 34.9 mmol) and Int 2 (7.65 g, 34.9 mmol) in EtOH (70 mL) stirs at rt for 15 h and is then concentrated *in vacuo*. The residue is diluted

with ether (100 mL) and saturated aqueous NaHCO₃ solution (100 mL). The organic layer is separated and dried over Na₂SO₄, filtered and concentrated *in vacuo*. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (85:15) affords Int 3 as a clear oil (76% yield): ¹H NMR (CDCl₃) δ 7.4-7.3, 4.8-4.7, 4.1, 3.8-3.6, 3.3-3.0, 2.7-2.6, 2.4-2.3, 1.2.

Step D. Preparation of *trans*-4-amino-1-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 4).

A mixture of Int 3 (3.28 g, 11.2 mmol) and RaNi (1.5 g) in EtOH (100 mL) is placed in a Parr bottle and hydrogenated for 4 h under an atmosphere of hydrogen (46 psi) at rt. The mixture is filtered through a pad of Celite, and the solvent is removed *in vacuo* to afford Int 4 as a clear oil (100% yield): ¹H NMR (300 MHz, CDCl₃) δ 7.3-7.2, 4.1, 3.6, 3.2, 3.0-2.9, 2.8, 2.8-2.6, 2.6-2.4, 2.30-2.2, 1.2.

Step E. Preparation of *trans*-4-(1,1-dimethylethoxycarbonylamido)-1-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 5).

Di-*tert*-butyldicarbonate (3.67 g, 16.8 mmol) is added to a stirred solution of Int 4 (2.94 g, 11.2 mmol) in CH₂Cl₂ (30 mL) cooled in an ice bath. The reaction is allowed to warm to rt and stirred overnight. The mixture is concentrated *in vacuo*. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (80:20) affords Int 5 as a white solid (77% yield): ¹H NMR (300 MHz, CDCl₃) δ 7.4-7.2, 5.1-4.9, 4.1, 4.0-3.8, 3.6, 3.2-3.0, 2.8-2.6, 2.5-2.4, 2.3-2.1, 1.4, 1.3.

Step F. Preparation of *trans* (tert-butoxycarbonylamino)-4-(2-hydroxyethyl)-1-(N-phenylmethyl) pyrrolidine (Int 6).

LiAlH₄ powder (627 mg, 16.5 mmol) is added in small portions to a stirred solution of Int 5 (3.0 g, 8.3 mmol) in anhydrous THF (125 mL) in a -5°C bath. The mixture is stirred for 20 min in a -5°C bath, then quenched by the sequential addition of water (0.6 mL), 15% (w/v) aqueous NaOH (0.6 mL) and water (1.8 mL). Excess anhydrous K₂CO₃ is added, and the mixture is stirred for 1 h, then filtered. The filtrate is concentrated *in vacuo*. The residue is purified by flash chromatography on

silica gel. Elution with EtOAc affords Int 6 as a white solid (94% yield): ^1H NMR (CDCl_3) δ 7.4-7.3, 5.3-5.2, 4.1-4.0, 3.9-3.7, 3.3-3.2, 2.8-2.7, 2.3-2.1, 1.7, 1.5.

Int 6 is a racemic mixture that can be resolved via chromatography using a
5 Diacel chiral pack AD column. From the two enantiomers thus obtained, the
(+)-enantiomer, $[\alpha]^{25}_{\text{D}} +35$ (c 1.0, MeOH), gives rise to the corresponding optically
pure *exo*-4-*S* final compounds, whereas the (-)-enantiomer, $[\alpha]^{25}_{\text{D}} -34$ (c 0.98,
MeOH), gives rise to optically pure *exo*-4-*R* final compounds. The methods described
herein use the (+)-enantiomer of Int 6 to obtain the optically pure *exo*-4-*S* final
10 compounds. However, the methods used are equally applicable to the (-)-enantiomer
of Int 6, making non-critical changes to the methods provided herein to obtain the
optically pure *exo*-4-*R* final compounds.


Step G. Preparation of *exo* 3-(*tert*-butoxycarbonylamino)-1-
15 azabicyclo[2.2.1]heptane (Int 7).

TEA (8.0 g, 78.9 mmol) is added to a stirred solution of Int 6 (2.5 g, 7.8 mmol)
in CH_2Cl_2 (50 mL), and the reaction is cooled in an ice-water bath. $\text{CH}_3\text{SO}_2\text{Cl}$ (5.5 g,
47.8 mmol) is then added dropwise, and the mixture is stirred for 10 min in an ice-
water bath. The resulting yellow mixture is diluted with saturated aqueous NaHCO_3
20 solution, extracted with CH_2Cl_2 several times until no product remains in the aqueous
layer by TLC. The organic layers are combined, washed with brine, dried over
 Na_2SO_4 and concentrated *in vacuo*. The residue is dissolved in EtOH (85 mL) and is
heated to reflux for 16 h. The reaction mixture is allowed to cool to rt, transferred to a
Parr bottle and treated with 10% Pd/C catalyst (1.25 g). The bottle is placed under an
25 atmosphere of hydrogen (53 psi) for 16 h. The mixture is filtered through Celite, and
fresh catalyst (10% Pd/C, 1.25 g) is added. Hydrogenolysis continues overnight. The
process is repeated three more times until the hydrogenolysis is complete. The final
mixture is filtered through Celite and concentrated *in vacuo*. The residue is purified
by flash chromatography on silica gel. Elution with CHCl_3 -MeOH- NH_4OH
30 (90:9.5:0.5) affords Int 7 as a white solid (46% yield): ^1H NMR (CDCl_3) δ 5.6-5.5,
3.8-3.7, 3.3-3.2, 2.8-2.7, 2.0-1.8, 1.7-1.5, 1.5.

Step H. Preparation of *exo*-3-amino-1-azabicyclo[2.2.1]heptane bis(hydro-*para*-toluenesulfonate).

Para-toluenesulfonic acid monohydrate (1.46 g, 7.68 mmol) is added to a stirred solution of Int 7 (770 mg, 3.63 mmol) in EtOH (50 mL). The reaction mixture is heated to reflux for 10 h, followed by cooling to rt. The precipitate is collected by vacuum filtration and washed with cold EtOH to give *exo*-[2.2.1]-Amine as a white solid (84% yield): ¹H NMR (CD₃OD) δ 7.7, 7.3, 3.9-3.7, 3.7-3.3, 3.2, 2.4, 2.3-2.2, 1.9-1.8. The corresponding amines can be obtained by using the resolved Int 6 to give *exo*-(4*R*)-[2.2.1]-3-Amine and *exo*-(4*S*)-[2.2.1]-3-Amine.

Synthesis of *endo*-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro *para*-toluenesulfonate) salt:



Step I. Preparation of ethyl 5-hydroxy-6-oxo-1,2,3,6-tetrahydropyridine-4-carboxylate (Int 10).

Absolute EtOH (92.0 mL, 1.58 mol) is added to a mechanically stirred suspension of potassium ethoxide (33.2 g, 395 mmol) in dry toluene (0.470 L). When the mixture is homogeneous, 2-pyrrolidinone (33.6 g, 395 mmol) is added, and then a solution of diethyl oxalate (53.1 mL, 390 mmol) in toluene (98 mL) is added via an addition funnel. After complete addition, toluene (118 mL) and EtOH (78 mL) is added sequentially. The mixture is heated to reflux for 18 h. The mixture is cooled to rt and aqueous HCl (150 mL of a 6.0 M solution) is added. The mixture is mechanically stirred for 15 min. The aqueous layer is extracted with CH₂Cl₂, and the combined organic layers are dried over MgSO₄, filtered and concentrated *in vacuo* to a

yellow residue. The residue is recrystallized from EtOAc to afford Int 10 as a yellow solid (38% yield): ^1H NMR (CDCl_3) δ 11.4, 7.4, 4.3, 3.4, 2.6, 1.3.

Step J. Preparation of ethyl *cis*-3-hydroxy-2-oxopiperidine-4-carboxylate (Int 11).
5 11).

A mixture of Int 10 (15 g, 81 mmol) and 5% rhodium on carbon (2.0 g) in glacial acetic acid is placed under an atmosphere of hydrogen (52 psi). The mixture is shaken for 72 h. The mixture is filtered through Celite, and the filtrate is concentrated *in vacuo* to afford Int 11 as a white solid (98% yield): ^1H NMR (CDCl_3) δ 6.3, 4.2,
10 4.0-3.8, 3.4, 3.3-3.2, 2.2, 1.3.

Step K. Preparation of *cis*- 4-(hydroxymethyl)piperidin-3-ol (Int 12).

Int 11 (3.7 g, 19.9 mmol) as a solid is added in small portions to a stirred solution of LiAlH_4 in THF (80 mL of a 1.0 M solution) in an ice-water bath. The
15 mixture is warmed to rt, and then the reaction is heated to reflux for 48 h. The mixture is cooled in an ice-water bath before water (3.0 mL, 170 mmol) is added dropwise, followed by the sequential addition of NaOH (3.0 mL of a 15% (w/v) solution) and water (9.0 mL, 500 mmol). Excess K_2CO_3 is added, and the mixture is stirred vigorously for 15 min. The mixture is filtered, and the filtrate is concentrated
20 *in vacuo* to afford Int 12 as a yellow powder (70% yield): ^1H NMR ($\text{DMSO}-d_6$) δ 4.3, 4.1, 3.7, 3.5-3.2, 2.9-2.7, 2.5-2.3, 1.5, 1.3.

Step L. Preparation of benzyl *cis*-3-hydroxy-4-(hydroxymethyl)piperidine-1-carboxylate (Int 13).

25 *N*-(benzyloxy carbonyloxy)succinimide (3.04 g, 12.2 mmol) is added to a stirred solution of Int 12 (1.6 g, 12.2 mmol) in saturated aqueous NaHCO_3 (15 mL) at rt. The mixture is stirred at rt for 18 h. The organic and aqueous layers are separated. The aqueous layer is extracted with ether (3X). The combined organic layers are dried over anhydrous K_2CO_3 , filtered and concentrated *in vacuo* to afford Int 13 as a yellow
30 oil (99% yield): ^1H NMR (CDCl_3) δ 7.4-7.3, 5.2, 4.3, 4.1, 3.8-3.7, 3.0-2.8, 2.1, 1.9-1.7, 1.4.

Step M. Preparation of benzyl *cis*-3-hydroxy-4-[(4-methylphenyl)sulfonyl oxymethyl]piperidine-1-carboxylate (Int 14).

Para-toluenesulfonyl chloride (1.0 g, 5.3 mmol) is added to a stirred solution of Int 13 (3.6 g, 5.3 mmol) in pyridine (10 mL) in a -15°C bath. The mixture is stirred for 4 h, followed by addition of HCl (4.5 mL of a 6.0 M solution). CH₂Cl₂ (5 mL) is added. The organic and aqueous layers are separated. The aqueous layer is extracted with CH₂Cl₂. The combined organic layers are washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo* to afford Int 14 as a colorless oil (78% yield): ¹H NMR (CDCl₃) δ 7.8, 7.4-7.2, 5.1, 4.3-4.2, 4.1, 3.9-3.8, 2.9-2.7, 2.4, 1.9, 1.6-1.3.

10

Step N. Preparation of *exo*-1-azabicyclo[2.2.1]heptan-3-ol (Int 15).

A mixture of Int 14 (3.6 g, 8.6 mmol) and 10% Pd/C catalyst (500 mg) in EtOH (50 mL) is placed under an atmosphere of hydrogen. The mixture is shaken for 16 h. The mixture is filtered through Celite. Solid NaHCO₃ (1.1 g, 13 mmol) is added to the filtrate, and the mixture is heated in an oil bath at 50°C for 5 h. The solvent is removed *in vacuo*. The residue is dissolved in saturated aqueous K₂CO₃ solution. Continuous extraction of the aqueous layer using a liquid-liquid extraction apparatus (18 h), followed by drying the organic layer over anhydrous K₂CO₃ and removal of the solvent *in vacuo* affords Int 15 as a white solid (91% yield): ¹H NMR δ 3.8, 3.0-2.8, 2.6-2.5, 2.4-2.3, 1.7, 1.1.

20

Step O. Preparation of *endo*-3-azido-1-azabicyclo[2.2.1]heptane (Int 16).

To a mixture of Int 15 (1.0 g, 8.9 mmol) and triphenyl phosphine (3.0 g, 11.5 mmol) in toluene-THF (50 mL, 3:2) in an ice-water bath are added sequentially a solution of hydrazoic acid in toluene (15 mL of ca. 2 M solution) and a solution of diethyl azadicarboxylate (1.8 mL, 11.5 mmol) in toluene (20 mL). The mixture is allowed to warm to rt and stir for 18 h. The mixture is extracted with aqueous 1.0M HCl solution. The aqueous layer is extracted with EtOAc, and the combined organic layers are discarded. The pH of the aqueous layer is adjusted to 9 with 50% aqueous NaOH solution. The aqueous layer is extracted with CH₂Cl₂ (3X), and the combined organic layers are washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The crude product is purified by flash chromatography on silica gel. Elution

30

with CHCl_3 -MeOH- NH_4OH (92:7:1) affords Int 16 as a colorless oil (41% yield): ^1H NMR (CDCl_3) δ 4.1, 3.2, 2.8, 2.7-2.5, 2.2, 1.9, 1.5.

Step P. Preparation of *endo*-3-amino-1-azabicyclo[2.2.1]heptane bis(hydro-
5 *para*-toluenesulfonate).

A mixture of Int 16 (250 mg, 1.8 mmol) and 10% Pd/C catalyst (12 mg) in EtOH (10 mL) is placed under an atmosphere of hydrogen (15 psi). The mixture is stirred for 1 h at rt. The mixture is filtered through Celite, and the filtrate is concentrated *in vacuo*. The residue is dissolved in EtOH (10 mL) and *para*-
10 toluenesulfonic acid monohydrate (690 mg, 3.7 mmol) is added. The mixture is stirred for 30 min, and the precipitate is filtered. The precipitate is washed sequentially with cold EtOH and ether. The precipitate is dried *in vacuo* to afford *endo*-[2.2.1]-Amine as a white solid (85% yield): ^1H NMR (CD_3OD) δ 7.7, 7.3, 4.2, 3.9, 3.6-3.4, 3.3-3.2, 2.4, 2.3, 2.1.

15

Preparation of the 3.2.1-Amine:

exo-1-Azabicyclo[3.2.1]octan-3-amine dihydrochloride (*exo*-[3.2.1]-
Amine):

A mixture of 1-azabicyclo[3.2.1]octan-3-one hydrochloride (2.80 g, 17.3
20 mmol), ethanol (25 mL), and hydroxylamine hydrochloride (1.56 g, 22.4 mmol) is treated with sodium acetate trihydrate (7.07 g, 51.2 mmol). The mixture is stirred for 3 h and evaporated *in vacuo*. The residue is diluted with CH_2Cl_2 , treated with charcoal, filtered and evaporated. The resulting material is taken up in 1-propanol (45 mL) and heated in a 100 °C oil bath. The solution is treated with sodium metal (6.4 g
25 in portions). Heating is continued for 3 h and the mixture cooled to rt. Water is added carefully and the organic layer is extracted, dried (MgSO_4), filtered, acidified with MeOH/HCl(g), and evaporated. 2-Propanol is added and the resulting solid is filtered and dried *in vacuo* to give *exo*-[3.2.1]-Amine in 49% yield. MS for $\text{C}_7\text{H}_{14}\text{N}_2 \cdot (\text{HCl})_2$ (ESI) ($\text{M} + \text{H}$) $^+$ m/z = 127.

30

endo-1-Azabicyclo[3.2.1]octan-3-amine dihydrochloride (*endo*-[3.2.1]-
Amine):


A mixture of 1-azabicyclo[3.2.1]octan-3-one hydrochloride (2.80 g, 17.3 mmol), ethanol (25 mL), and hydroxylamine hydrochloride (1.56 g, 22.4 mmol) is treated with sodium acetate trihydrate (7.07 g, 51.2 mmol). The mixture is stirred for 3 h and evaporated *in vacuo*. The residue is diluted with CH₂Cl₂, treated with charcoal, filtered and evaporated. The resulting oxime (3.1 mmol) is treated with acetic acid (30 mL) and hydrogenated at 50 psi over PtO₂ (50 mg) for 12 h. The mixture is then filtered and evaporated. The residue is taken up in a minimal amount of water (6 mL) and the pH is adjusted to >12 using solid NaOH. The mixture is then extracted with ethyl acetate (4 X 25 mL), dried over MgSO₄, filtered, treated with ethereal HCl, and evaporated to give *endo*-[3.2.1]-Amine.

1-Azabicyclo[3.2.1]octan-3-amine:

Preparation of the 3*R*,5*R*-[3.2.1]-Amine:


This amine can also be prepared according to the following method:

(3*S*)-1-[(*S*)-1-Phenethyl]-5-oxo-3-pyrrolidine-carboxylic acid:




According to the literature procedure (Nielsen *et al.* J. Med. Chem 1990, 70-77), a mixture of itaconic acid (123.17 g, 946.7 mmol) and (*S*)-(-)- α -methyl benzylamine (122.0 mL, 946.4 mmol) are heated (neat) in a 160°C oil bath for 4 h. Upon cooling, MeOH (~200 mL) is added and the resulting solid collected by filtration. The solid is treated with EtOH (~700 mL) and warmed using a steam bath until ~450 mL solvent remained. After cooling to rt, the solid is collected and dried to afford 83.2 g as a crystalline solid: $[\alpha]^{25}_D = -80$ (*c* 0.97, DMSO). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.66, 7.20-7.40, 5.23, 3.40-3.55, 3.10-3.25, 2.40-2.65, 1.45; MS (EI) *m/z* 233 (*M*⁺).

(3*S*)-1-[(*S*)-1-Phenethyl]-3-(hydroxymethyl)pyrrolidine:



A suspension (3*S*)-1-[(*S*)-1-phenethyl]-5-oxo-3-pyrrolidine-carboxylic acid (82.30 g, 352.8 mmol) in Et₂O (200 mL) is added in small portions to a slurry of LiAlH₄ (17.41 g, 458.6 mmol) in Et₂O (700 mL). The mixture begins to reflux during the addition. The addition funnel containing the suspension is rinsed with Et₂O (2 x 50 mL), and the mixture is heated in a 50 °C oil bath for an additional 2 h and first allowed to cool to rt and then further cooled using an ice bath. The mixture is carefully treated with H₂O (62 mL). The resulting precipitate is filtered, rinsed with Et₂O, and discarded. The filtrate is concentrated to a yellow oil. When EtOAc is added to the oil, a solid began to form. Hexane is then added, and the mixture is filtered and the solid is dried to afford 43.3 g. $[\alpha]_D^{25} = -71$ (*c* 0.94, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.20-7.45, 3.60-3.70, 3.40-3.60, 3.19, 3.05-3.15, 2.35-2.55, 2.25-2.35, 1.95-2.10, 1.75-1.90, 1.42; HRMS (FAB) calcd for C₁₃H₁₉NO (MH⁺) 206.1545, found 206.1532.


(3*R*)-1-[(*S*)-1-Phenethyl]-3-(cyanomethyl)pyrrolidine:



A solution of (3*S*)-1-[(*S*)-1-phenethyl]-3-(hydroxymethyl)pyrrolidine (42.75 g, 208.23 mmol) in chloroform (350 mL) is heated to reflux under N₂. The solution is treated with a solution of thionyl chloride (41.8 mL, 573 mmol) in chloroform (40 mL) dropwise over 45 min. The mixture is stirred for an additional 30 min, is cooled and concentrated. The residue is diluted with H₂O (~200 mL), 1 N NaOH is added until a pH ~ 8 (pH paper). A small portion (~50 mL) of sat. NaHCO₃ is added and the basic mixture is extracted with EtOAc (3 x 400 mL), washed with brine, dried over MgSO₄, filtered and concentrated to give 46.51 g of (3*S*)-1-[(*S*)-1-phenethyl]-3-(chloromethyl)pyrrolidine: MS (ESI⁺) *m/z* 224.2 (MH⁺). The chloride (46.35 g, 208.0 mmol) is transferred to a flask, DMSO (200 mL) is added, and the solution is

treated with NaCN (17.84 g, 363.9 mmol). The mixture is heated under N₂ in a 100°C oil bath overnight and is cooled. The brown mixture is poured into H₂O (300 mL) and is extracted with EtOAc (1000 mL in portions). The combined organic layer is washed with H₂O (6 x ~50 mL), brine (~100 mL), dried (MgSO₄), filtered and concentrated to give 40.61 g of an oil: ¹H NMR (400 MHz, CDCl₃) δ 7.20-7.40, 3.26, 2.70-2.85, 2.40-2.60, 2.27, 2.10-2.20, 1.50-1.70, 1.41; MS (ESI+) for *m/z* 215.2 (M+H⁺).

(3R)-Methyl 1-[(S)-1-phenylethyl]pyrrolidine-3-acetate:




10

Acetyl chloride (270 mL, 3.8 mol) is carefully added to a flask containing chilled (0°C) methanol (1100 mL). After the addition is complete, the acidic solution is stirred for 45 min (0 °C) and then (3R)-1-[(S)-1-phenethyl]-3-(cyanomethyl)pyrrolidine (40.50 g, 189.0 mmol) in methanol (200 mL) is added. The ice bath is removed and the mixture is stirred for 100 h at rt. The resulting suspension is concentrated. Water (~600 mL) is added, the mixture stirred for 45 min and then the pH is adjusted (made basic) through the addition of ~700 mL sat. aq. NaHCO₃. The mixture is extracted with EtOAc (3 x 300 mL). The combined organic layers are washed with brine, dried (MgSO₄), filtered through celite and concentrated to give 36.86 g as an oil: ¹H NMR (400 MHz, CDCl₃) δ 7.20-7.40, 3.69, 3.30-3.40, 2.85-2.95, 2.40-2.70, 2.00-2.20, 1.10-1.65; MS (ESI+) *m/z* 248.2 (M+H⁺).

20

(5R)-1-Azabicyclo[3.2.1]octan-3-one hydrochloride:




25

A solution of (3R)-methyl 1-[(S)-1-phenylethyl]pyrrolidine-3-acetate (25.72 g, 104.0 mmol) in THF (265 mL) is cooled under N₂ in a CO₂/acetone bath. Next,

ICH_2Cl (22.7 mL, 312.0 mmol) is added, and the mixture stirred for 30 min. A solution of 2.0M lithium diisopropylamide (heptane/THF/ethylbenzene, 156 mL, 312 mmol) is added slowly over 30 min. The internal temperature reached a maximum of -40°C during this addition. After 1 h, sat. NH_4Cl (100 mL) is added and the mixture
 5 is allowed to warm to rt. The organic layer is separated, dried (MgSO_4), filtered and concentrated. The resulting foam is chromatographed (300 g SiO_2 , CHCl_3 -MeOH- NH_4OH (89:10:1) followed by CHCl_3 -MeOH (3:1). The product fractions are pooled and concentrated to afford (5*R*)-3-oxo-1-[(1*S*)-1-phenylethyl]-1-azoniabicyclo[3.2.1]octane chloride (10.12g) as a foam (MS (ESI+) m/z 230.1
 10 ($\text{M}+\text{H}^+$). This foam (10.1 g, 38 mmol) is taken up in MeOH (500 mL), 10% Pd(C) (3.0 g) added and the mixture is hydrogenated (45 psi) overnight. The mixture is filtered and re-subjected to the reduction conditions (9.1 g, 10% Pd/C, 50 psi). After 5 h, TLC indicates the consumption of the (5*R*)-3-oxo-1-[(1*S*)-1-phenylethyl]-1-azoniabicyclo[3.2.1]octane chloride. The mixture is filtered, concentrated and
 15 triturated (minimal *i*PrOH) to give 3.73 g in two crops, as a solid: $[\alpha]_D^{25} = 33$ (c 0.97, DMSO); HRMS (FAB) calcd for $\text{C}_7\text{H}_{11}\text{NO}$ ($\text{M}+\text{H}^+$) 126.0919, found 126.0937.


(3*R*,5*R*)-1-azabicyclo[3.2.1]octan-3-amine dihydrochloride:



20 To a flask containing (5*R*)-1-azabicyclo[3.2.1]octan-3-one hydrochloride (3.64 g, 22.6 mmol), hydroxylamine hydrochloride (2.04 g, 29.4 mmol), and ethanol (130 mL) is added sodium acetate trihydrate (9.23 g, 67.8 mmol). The mixture stirred for 3 h and is filtered and concentrated. The resulting white solid is taken up in *n*-propanol (100 mL) and sodium (~13.6 g, 618 mmol) is added in 20-25 portions. The reaction
 25 spontaneously begins to reflux, and the reaction is heated in an oil bath (100°C). The addition is complete in ~20 min and the mixture solidifies after ~40 min. The oil bath is removed and *n*-propanol (2 x 25 mL) is added dissolving the remaining sodium metal. The mixture is carefully quenched through the dropwise addition of H_2O (100 mL). Saturated aq. NaCl (20 mL) is added, and the layers are separated. The organic

layer is dried (MgSO_4), filtered, treated with freshly prepared MeOH/HCl , and concentrated. The resulting solid is triturated with 30 mL EtOH , filtered and dried *in vacuo* to afford 3.51 g as a white solid: $[\alpha]_D^{25} = -3$ (c 0.94, DMSO); ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 3.60-3.80, 2.95-3.10, 2.65-2.75, 1.90-2.15, 1.70-1.90; HRMS (FAB) calcd for $\text{C}_7\text{H}_{14}\text{N}_2$ ($\text{M}+\text{H}^+$) 127.1235, found 127.1235.

Preparation of the 3.2.2 Amines:



Preparation of tert-butyl 4-(2-oxopropylidene)piperidine-1-carboxylate (Int 101):

Sodium hydride (60% oil dispersion, 2.01 g, 50.2 mmol) was washed with pentane (3X) and suspended in dry THF (40 mL). The solution was cooled to 0°C before diethyl (2-oxopropyl)phosphonate (9.75 g, 50.2 mmol) was added dropwise. After complete addition, the solution was warmed to rt and stirred for 30 min. *tert*-Butyl 4-oxo-1-piperidinecarboxylate (5.0g, 25.1 mmol) was added in portions over 10 min, followed by stirring at rt for 2 h. A saturated aqueous solution of ammonium chloride was added, followed by dilution with ether. The organic layer was extracted with water. The organic layer is dried over anhydrous MgSO_4 , filtered and concentrated to a yellow oil. The crude product was purified by flash chromatography on silica gel. Elution with hexanes-ether (60:40) gave 4.5 g (75%) of Int 101 as a white solid: ^1H NMR (CDCl_3) δ 6.2, 3.5, 3.4, 2.9, 2.3, 2.2, 1.5.

Preparation of tert-butyl 4-(2-oxopropyl)piperidine-1-carboxylate (Int 102):

A mixture of Int 101 (4.5 g, 19 mmol) and 10% palladium on activated carbon (450mg) in EtOH (150 mL) was placed in a Parr bottle and hydrogenated for 5 h at 50

psi. The mixture was filtered through Celite, and the filtrate was concentrated *in vacuo* to afford 4.3 g (94%) of Int 102 as a clear oil: ^1H NMR (CDCl_3) δ 4.1, 2.8, 2.4, 2.2, 2.0, 1.7, 1.5, 1.1.

5 Preparation of tert-butyl 4-(3-bromo-2-oxopropyl)piperidine-1-carboxylate (Int 103):

To a stirred solution lithium hexamethyldisilylamide in THF (20.0 mL, 1.0 M) in a -78°C bath was added chlorotrimethylsilane (11.0 mL, 86.4 mmol) dropwise. The mixture was stirred at -78°C for 20 min, followed by addition of 102 (3.21 g, 10 13.3 mmol) in a solution of THF (50 mL) dropwise. After complete addition, the mixture was stirred at -78°C for 30 min. The mixture was warmed to 0°C in an ice-water bath and phenyltrimethylammonium tribromide (5.25 g, 14.0 mmol) was added. The mixture was stirred in an ice-bath for 30 min, followed by the addition of water and ether. The aqueous layer was washed with ether, and the combined organic layers 15 were washed with saturated aqueous sodium thiosulfate solution. The organic layer was dried over anhydrous MgSO_4 , filtered and concentrated *in vacuo* to afford a yellow oil. The crude product was purified by flash chromatography on silica gel. Elution with hexanes-ether (60:40) gave 2.2 g (52%) of Int 103 as a lt. yellow oil: ^1H NMR (CDCl_3) δ 4.2-4.1, 3.9, 2.8, 2.7, 2.6, 2.1-2.0, 1.7, 1.5, 1.2-1.1.2.

20

Preparation of 1-bromo-3-piperidin-4-ylacetone trifluoroacetate (Int 104):

To a stirred solution of 103 (2.2 g, 6.9 mmol) in CH_2Cl_2 (30 mL) in an ice-water bath was added trifluoroacetic acid (10 mL, 130 mmol). The mixture was stirred at 0°C for 30 min. The volatiles were removed *in vacuo* to afford 2.0 g (87%) 25 of Int 104 as a yellow residue: MS (ESI) for $\text{C}_8\text{H}_{15}\text{BrNO}$ $[\text{M}+\text{H}]^+ m/e$ 220.

Preparation of 1-azabicyclo[3.2.2]nonan-3-one (Int 105):

To a stirred solution of DIEA (13 mL) in acetonitrile (680 mL) at reflux temperature was added a solution of Int 104 (2.0 g, 6.0 mmol) in acetonitrile (125 mL) 30 over a 4 h period via syringe pump. The mixture was kept at reflux temperature overnight. The mixture was concentrated *in vacuo* and the remaining residue was partitioned between a saturated aqueous K_2CO_3 solution and CHCl_3 -MeOH (90:10). The aqueous layer was extracted with CHCl_3 -MeOH (90:10), and the combined

organic layers were dried over MgSO_4 , filtered and concentrated *in vacuo* to a brown oil. The crude product was purified by flash chromatography on silica gel. Elution with CHCl_3 -MeOH- NH_4OH (95:4.5:0.5) gave 600 mg (72%) of Int 105 as a clear solid: ^1H NMR (CDCl_3) δ 3.7, 3.3-3.2, 3.1-3.0, 2.7, 2.3, 2.0-1.8.

5

Preparation of 1-azabicyclo[3.2.2]nonan-3-amine bis(4-methylbenzenesulfonate) ([3.2.2]-Amine):

To a stirred mixture of Int 105 (330 mg, 2.4 mmol) and sodium acetate•trihydrate (670 mg, 4.8 mmol) in EtOH (6.0 mL) was added hydroxylamine•hydrochloride (200 mg, 2.8 mmol). The mixture was stirred at rt for 10 h. The mixture was filtered and the filtrate was concentrated *in vacuo* to a yellow solid. To a solution of the solid (350 mg, 2.3 mmol) in *n*-propanol (30 mL) at reflux temperature was added sodium metal (2.0 g, 87 mmol) in small portions over 30 min. Heating at reflux was continued for 2 h. The solution is cooled to rt and brine is added. The mixture is extracted with *n*-propanol, and the combined organic layers are concentrated *in vacuo*. The residue was taken up in CHCl_3 and the remaining solids were filtered. The filtrate was dried over anhydrous MgSO_4 , filtered and concentrated *in vacuo* to a clear solid. To a stirred solution of the solid (320 mg, 2.3 mmol) in EtOH (4 mL) was added *p*-toluenesulfonic acid monohydrate (875 mg, 4.6 mmol). The solution was warmed in a water bath to 45°C for 30 min, followed by concentration of the solvent to afford 710 mg (62%) of [3.2.2]-Amine as a white solid: ^1H NMR (CD_3OD) δ 7.7, 7.3, 4.1-3.9, 3.6-3.4, 2.6-2.5, 2.4, 2.2-2.1, 2.1-2.0, 1.9.

15

20

Resolution of stereoisomers:

25

The amine can be coupled to form the appropriate amides or thioamides as a racemic mixture. The racemic mixture can then be resolved by chromatography using chiral columns or chiral HPLC, techniques widely known in the art, to provide the requisite resolved enantiomers 3(R) and 3(S) of said amides or thioamides.


30

Preparation of Acids and Coupling to Appropriate Amine:

The following examples are provided as examples and are not intended to limit the scope of this invention to only those provided examples and named compounds. Also, the salts made in the examples are only exemplary and are not

intended to limit the invention. Any pharmaceutically acceptable salt can be made by one of ordinary skill in the art. Further, the naming of specific stereoisomers is for exemplification, and is not intended to limit in anyway the scope of the invention. The invention includes the following examples in pure stereoisomeric form or as
5 racemic mixtures.

Example 1: *N*-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide•fumarate:



10 A mixture of 4-amino-3-hydroxybenzoic acid (1.0 g, 6.5 mmol) and trimethyl orthoformate (2.0 mL, 18.3 mmol) is heated in an oil bath at 100°C for 30 h. The mixture is cooled to rt and diluted with MeOH. The resulting solution is filtered through a pad of Celite, and the filtrate is concentrated *in vacuo* to give 1,3-benzoxazole-5-carboxylic acid as a brown solid (290 mg, 27%): ¹H NMR (DMSO-*d*₆)
15 δ 13.0, 8.9, 8.3, 8.1, 7.9.

Coupling:


To a stirred solution of 1,3-benzoxazole-5-carboxylic acid (290 mg, 1.78 mmol) in dry DMF (15 mL) is added DIEA (928 μL, 5.34 mmol), followed by *exo*-4(*S*)-[2.2.1]-Amine (740 mg, 1.62 mmol). The solution is cooled with an ice bath
20 before 676 mg (1.78 mmol) of HATU is added. The solution is allowed to warm to rt and stir for 16 h. The solvent is removed *in vacuo*, and the remaining residue is partitioned between saturated aqueous K₂CO₃ solution and 9:1 chloroform-methanol. The aqueous layer is extracted with 9:1 chloroform-methanol, and the combined organic layers are washed with brine, dried over MgSO₄, filtered and concentrated *in*
25 *vacuo* to afford the desired material as a yellow solid (401 mg, 96%): low-resolution MS (ESI) *m/e* 258 [M+H].

Salt formation:

To a stirred solution of the above amide (231 mg, 0.90 mmol) in acetone (5 mL) is added a hot solution of fumaric acid (100 mg, 0.90 mmol) in IPA (2 mL). The
30 mixture is stirred for 30 min at 50°C. The solvents are removed *in vacuo*, acetone (5 mL) is added. The mixture is stirred overnight at rt. The solid is collected by

filtration and washed with acetone. The solid is dried under high vacuum overnight to give 160 mg (50%) of the title compound as an off-white solid: HRMS (FAB) calculated for $C_{14}H_{16}N_3O_2$ $[M+H]^+$ m/e 258.1242, found 258.1239.

- 5 **Example 2:** *N*-(1-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-5-carboxamide:




- A mixture of 4-amino-3-hydroxybenzoic acid (480 mg, 3.1 mmol) and trimethyl orthoacetate (1.0 mL, 7.9 mmol) are heated in an oil bath to 107°C for 2 h.
- 10 The mixture is cooled to rt and diluted with MeOH. The resulting solution is filtered through a pad of silica gel and the filtrate is concentrated *in vacuo* to give 2-methyl-1,3-benzoxazole-5-carboxylic acid as an orange solid (490 mg, 88%): 1H NMR (DMSO- d_6) δ 13.0, 8.2, 8.0, 7.8, 2.7.

Coupling:

- 15 2-Methyl-1,3-benzoxazole-5-carboxylic acid can be coupled with the *exo*- or *endo*-[2.2.1]-Amine using procedures discussed herein to obtain Example 2(i).

Example 3: *N*-(1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-6-carboxamide:




- 20 A mixture of 4-amino-3-hydroxybenzoic acid (250 mg, 1.63 mmol) and trimethyl orthoformate (500 μ L, 4.57 mmol) are heated in an oil bath at 100°C for 2 h. The mixture is cooled to rt and diluted with MeOH. The resulting solution is filtered through a pad of Celite, and the filtrate is concentrated *in vacuo* to give 1,3-benzoxazole-6-carboxylic acid as a brown solid (237 mg, 89%): 1H NMR (DMSO- d_6)
- 25 δ 13.2, 8.9, 8.3, 8.0, 7.9.

Coupling:

- 1,3-Benzoxazole-6-carboxylic acid can be coupled with the *exo*- or *endo*-[2.2.1]-Amine using procedures discussed herein to obtain Example 3(i).

Example 4: *N*-(1-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-6-carboxamide:




- 5 A mixture of 4-amino-3-hydroxybenzoic acid (500 mg, 3.7 mmol) and trimethyl orthoacetate (1.0 mL, 7.9 mmol) is heated in an oil bath to 100°C for 2 h. The mixture is cooled to rt and diluted with MeOH. The resulting solution is filtered through a pad of Celite, and the filtrate is concentrated *in vacuo* to give 2-methyl-1,3-benzoxazole-6-carboxylic acid as an off-white solid (266 mg, 46%): ¹H NMR (DMSO-*d*₆) δ 13.1, 8.2, 8.0, 7.7, 2.7.
- 10

Coupling:

2-Methyl-1,3-benzoxazole-6-carboxylic acid can be coupled with the *exo*- or *endo*-[2.2.1]-Amine using procedures discussed herein to give Example 4(i).


- 15 **Example 5:** *N*-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzothiazole-6-carboxamide•fumarate:



Coupling and Salt formation:

- Using the procedure outlined for Example 1(i), 1,3-benzothiazole-6-carboxylic acid is coupled with the *exo*-[2.2.1]-Amine and the fumarate salt made to give the title compound in 75% yield. ¹H NMR (CD₃OD) δ 9.4, 8.6, 8.2, 8.1, 6.7, 4.3, 3.8, 3.5-3.4, 3.3-3.2, 3.1, 2.2, 1.9-1.8.
- 20

- Example 6:** *N*-[*exo*-(4*S*)-1-azabicyclo[2.2.1]hept-3-yl]-indane-5-carboxamide•fumarate:
- 25




To a stirred 6% aqueous sodium hypochlorite solution in an oil bath to 55°C is added 1-indane-5-yl-ethanone (1.0 g, 6.2 mmol). The solution is stirred at 55°C for 2 h, followed by cooling to rt. Solid sodium bisulfite is added until the solution becomes clear. The mixture is diluted with water, followed by aqueous hydrochloric acid (6.0 M). The solid that forms is filtered and washed several times with water. The solid is dried under high vacuum at 60°C for 5 h to afford 5-indancarboxylic acid as a white solid (0.96 g, 95%): ¹H NMR (CDCl₃) δ 8.0, 7.9, 7.3, 3.0, 2.1.

Coupling:

The free base of Example 6(i) is obtained in 99% using the coupling procedure for Example 1(i), making non-critical changes.

Salt formation: To a stirred solution of the free base (128 mg, 0.5 mmol) in MeOH (5 mL) is added a warm solution of fumaric acid (58 mg, 0.5 mmol) in MeOH (5 mL). The mixture is warmed to 40 °C for 10 min. The solvent is removed *in vacuo*, and the remaining residue is diluted with acetone (5 mL). The mixture is stirred overnight at rt. The solid precipitate is collected by filtration, washed with acetone, and dried *in vacuo* overnight to give 113 mg (59%) of Example 6(i) as a white solid: ¹H NMR (400 MHz, CD₃OD) δ 7.72, 7.64, 7.32, 6.71, 4.22-4.19, 3.71-3.66, 3.43-3.36, 3.25-3.19, 3.03, 2.97, 2.20-2.10, 1.86-1.79.

Example 7: *N*-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzodioxole-5-carboxamide•4-methylbenzenesulfonate:




To a stirred solution of piperonylic acid (166 mg, 1.0 mmol) in anhydrous DMF (10 mL) are added DIEA (530 μL, 3.05 mmol) and *exo*-(4*S*)-[2.2.1]-3-Amine (456 mg, 1.0 mmol). The mixture is cooled to 0°C in an ice bath, and HATU (380 mg, 0.5 mmol) is added in one portion. The reaction mixture is allowed to warm to rt and is stirred overnight. The solvent is removed *in vacuo*, and the residue is partitioned between saturated aqueous K₂CO₃ solution and chloroform. The aqueous layer is extracted with chloroform (2x). The combined organic layers are washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The crude product is

purified by flash chromatography on silica gel. Elution with CHCl_3 -MeOH- NH_4OH (89:9:1) gives 260 mg (99%) of the corresponding amide as a solid.

To a stirred solution of the amide (182 mg, 0.70 mmol) in MeOH (5 mL) is added a solution of *p*-toluenesulfonic acid monohydrate (133 mg, 0.70 mmol) in MeOH (5 mL). The mixture is stirred for 10 min at 50°C. The solvent is removed *in vacuo*, and the remaining residue is diluted with acetone (10 mL). The mixture is stirred overnight at rt. The solid precipitate is collected by filtration, washed with acetone, and dried under high vacuum overnight to give 191 mg (63.5%) of title compound as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 7.73-7.12, 7.48-7.45, 7.35, 7.26-7.24, 6.92-6.90, 6.06, 4.22-4.19, 3.75-3.70, 3.48-3.35, 3.30-3.25, 3.05-3.04, 2.39, 2.23-2.14, 1.88-1.81.

Example 8: *N*-[1-azabicyclo[2.2.1]hept-3-yl]-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide:



Preparation of the acid:

2-Chloro-3-pyridinol (20.0 g, 0.154 mole), NaHCO_3 (19.5g, 0.232 mole, 1.5 equ), and 150 mL of water are placed in a flask. The flask is placed in an oil bath at 90°C, and after 5 min, 37% aqueous formaldehyde (40.5 mL, 0.541 mole, 3.5 equ) is added in six unequal doses in the following order: 12 mL, 3 x 8 mL, then 2.2 mL all at 90-min intervals and then the final 2.3 mL after the reaction stirs for 15 h at 90°C. The reaction is stirred at 90°C for another 4 h and then cooled by placing the flask in

an ice bath. The pH of the reaction is then adjusted to 1 using 6N HCl. The reaction is stirred for 1.5 h in an ice bath allowing an undesired solid to form. The undesired solid is removed by filtration, and the filtrate is extracted seven times with EtOAc. The combined organic extracts are concentrated *in vacuo*, toluene is added to the flask and removed *in vacuo* to azeotrope water, and then CH₂Cl₂ is added and removed *in vacuo* to obtain 2-chloro-6-(hydroxymethyl)-3-pyridinol as a pale yellow solid (81% yield) sufficiently pure for subsequent reaction. MS (EI) for C₆H₆ClNO₂, *m/z*: 159(M)⁺.

2-Chloro-6-(hydroxymethyl)-3-pyridinol (11.6 g, 72.7 mmol) and NaHCO₃ (18.3 g, 218 mmol) are added to 200 mL water. The mixture is stirred until homogeneous; the flask is placed in an ice bath, iodine (19.4 g, 76.3 mmol) is added, and the reaction is stirred over the weekend at rt. The pH of the mixture is adjusted to 3 with 2N NaHSO₄, and the mixture is extracted with 4 x 50 mL EtOAc. The combined organic layer is dried over anhydrous MgSO₄, is filtered, and the filtrate is concentrated *in vacuo* to a yellow solid. The crude solid is washed with EtOAc to provide 2-chloro-6-(hydroxymethyl)-4-iodo-3-pyridinol as an off-white solid (62% yield), and the filtrate is concentrated to a small volume and is chromatographed over 250 g silica gel (230-400 mesh) eluting with 2.5:4.5:4:0.1 EtOAc/CH₂Cl₂/hexane/acetic acid. The desired fraction were combined and concentrated to afford additional pure (12% yield). MS (EI) for C₆H₅ClINO₂, *m/z*: 285(M)⁺.

4-(Benzylamino)-2-chloro-6-(hydroxymethyl)-3-pyridinol (C13) may be produced by amination of 2-chloro-6-(hydroxymethyl)-4-iodo-3-pyridinol (C12) with benzylamine under palladium catalysis. Amination of aryl iodides with primary amines such as benzylamine under palladium catalysis is generally described in a review by B.H. Yang and S.L. Buchwald in *J. Organomet. Chem.*, 576, 125-146, 1999 and in greater detail in the references therein.


4-(Benzylamino)-2-chloro-6-(hydroxymethyl)-3-pyridinol may be oxidized to 4-(benzylamino)-2-chloro-3-hydroxypyridine-6-carboxaldehyde (C14) under a wide variety of conditions (e.g., TPAP and NMO in CH₂Cl₂). 4-(Benzylamino)-2-chloro-3-hydroxypyridine-6-carboxaldehyde may be oxidized to produce the corresponding carboxylic acid C15 using an oxidizing reagent such as NaClO₂ and KH₂PO₄ in DMSO/H₂O or Ag₂O, or hydrogen peroxide or ruthenium tetroxide.

Removal of the benzyl group and the chloro group of Acid C15 may be accomplished by utilizing hydrogen or a hydrogen source (e.g., cyclohexene, cyclohexadiene, ammonium formate, hydrazine, etc.) in the presence of Pd/C or other catalyst, under a variety of conditions and in various solvents, to produce 4-amino-5-hydroxypyridine-2-carboxylic acid (Acid C16).

Cyclocondensation of Acid C16 with trimethyl orthoformate in the presence of catalytic *para*-toluenesulfonic acid may be conducted to produce [1,3]-oxazolo[5,4-*c*]pyridine-6-carboxylic acid (Acid C17).


[1,3]-Oxazolo[5,4-*c*]pyridine-6-carboxylic acid can be coupled with the *exo*- or *endo*-[2.2.1]-Amine using procedures discussed herein to give Example 8(i).

Example 9: *N*-[1-azabicyclo[2.2.1]hept-3-yl]-2-benzothiophene-5-benzamide:



Acid C21 can be made by the saponification of the methyl ester C20, which can be made pursuant to Wynberg, Hans, et al., *Recl. Trav. Chim. Pays-Bas* (1968), 87(10), 1006-1010. Acid C21 can then be coupled with the *exo*- or *endo*-[2.2.1]-Amine using methods discussed herein to provide Example 9 as the free base that can be made into a suitable salt.

Example 10: *N*-[*exo*-(4*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1*H*-indazole-5-carboxamide•fumarate:



To a stirred mixture of methyl 3-methyl-4-aminobenzoate (5.0 g, 30.0 mmol) and potassium acetate (2.94 g, 30.0 mmol) in chloroform (50 mL) is added acetic anhydride (5.66 mL, 60.0 mmol). The mixture is stirred for 30 min at rt, followed by the addition of 18-crown-6 (1.58 g, 6.0 mmol) and *n*-amyl nitrite (7.78 g, 66.0 mmol). The mixture is heated to reflux for 16 h, followed by cooling to rt. The mixture is washed sequentially with aqueous sodium bicarbonate solution (2X), water and brine.

The organic layer is dried over MgSO_4 , filtered and concentrated *in vacuo*. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (80:20) gives 3.1 g (47%) of methyl 1-acetyl-1*H*-indazole-5-carboxylate as a yellow solid: ^1H NMR (400 MHz, CDCl_3) δ 8.52-8.50, 8.3, 8.2, 4.0, 2.8.

5 To a stirred solution of methyl 1-acetyl-1*H*-indazole-5-carboxylate (1.16 g, 5.31 mmol) in methanol (10 mL) is added HCl (10 mL of a 6.0 M aqueous solution). The mixture is stirred at rt overnight. The methanol is removed *in vacuo*, and the remaining aqueous solution is basified with 30% aqueous NH_4OH to pH = 8. The resulting precipitate is collected by filtration, washed with water and dried *in vacuo* to afford 900 mg (96%) of methyl 1*H*-indazole-5-carboxylate as a light yellow solid: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.4, 8.5, 8.3, 7.9, 7.6, 3.9.


To a stirred solution of methyl 1*H*-indazole-5-carboxylate (500 mg, 2.84 mmol) in MeOH (15 mL) is added sodium hydroxide (20 mL of 2.5 % aqueous solution). The mixture is heated at reflux for 1 h, followed by removal of the methanol *in vacuo*. The remaining aqueous solution is washed with EtOAc (5 mL), 15 acidified with 1 N aqueous HCl to pH ~ 5-6. The resulting precipitate is collected by filtration, washed with water and dried *in vacuo* to afford 410 mg (89%) of 1*H*-indazole-5-carboxylic acid as a tan solid: IR (diffuse reflectance) 3290, 3115, 2964, 2954, 2813, 2606, 2557, 2505, 1687, 1627, 1321, 1274, 948, 937, 769 cm^{-1} ; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.4 12.7, 8.5 8.2, 7.9, 7.6.

To a stirred solution 1*H*-indazole-5-carboxylic acid (162 mg, 1.00 mmol) in anhydrous DMF (10 mL) are added DIEA (531 μL , 3.05 mmol) and *exo*-(4*S*)-[2.2.1]-3-amine (456 mg, 1.00 mmol). The mixture is cooled to 0°C, and HATU (380 mg, 1.00 mmol) is added in one portion. The reaction mixture is allowed to warm to rt and stirred overnight. The solvent is removed *in vacuo*, and the residue is partitioned 25 between saturated aqueous K_2CO_3 solution and chloroform. The aqueous layer is extracted with chloroform (4x). The combined organic layers are washed with brine, dried over Na_2SO_4 , filtered and concentrated *in vacuo*. The crude product is purified by flash chromatography on silica gel. Elution with CHCl_3 -MeOH- NH_4OH (89:9:1) gives 70 mg (27%) of the amide as a white solid.

30 To a stirred solution of the amide (70 g, 0.27 mmol) in MeOH (5 mL) is added a warm solution of fumaric acid (32 mg, 0.27 mmol) in MeOH (5 mL). The mixture is stirred for 10 min at 40°C. The solvent is removed *in vacuo*, and the remaining

residue is diluted with acetone (5 mL). The mixture is stirred overnight at rt. The solid precipitate is collected by filtration, washed with acetone, and dried under high vacuum overnight to give 82 mg (81%) of Example 10(i) as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 8.43, 8.35, 8.21, 7.87-7.84, 7.58-7.56, 6.53, 3.81, 3.15, 2.80, 2.70-2.60, 1.75, 1.35.

Example 11: *N*-[*exo*-(4*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1*H*-indazole-6-carboxamide•fumarate• H_2O :




To a stirred solution of aqueous HCl (15 mL of concentrated HCl and 50 mL of water) is added 3-amino-4-methyl benzoic acid (5.0 g, 33 mmol). The mixture is cooled in an acetone-ice water bath, followed by the slow addition of a solution of sodium nitrite (2.28 g, 33 mmol) in water (12 mL). The mixture is allowed to stir for 10 min at which point the mixture becomes homogeneous. A saturated aqueous solution of sodium acetate is added until pH~ 6. 2-Methylpropane-2-thiol (1.8 mL, 16 mmol) is added and the mixture is stirred for 1 h. The resulting precipitate is collected by filtration, washed with water and dried *in vacuo* to give 3.85 g (96%) of 3-(*tert*-butylthio)diazenyl-4-methylbenzoic acid as a tan solid: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.2, 7.8, 7.5, 7.3, 2.1, 1.6.

To a stirred solution of potassium *tert*-butoxide (8.14 g, 72.7 mmol) in DMSO (30 mL) is added a solution of 3-(*tert*-butylthio)diazenyl-4-methylbenzoic acid (1.85 g, 7.34 mmol) in DMSO (20 mL). The mixture is stirred overnight at rt. The mixture is diluted with ice-water, acidified with 1N aqueous HCl to a pH of about 5 to about 6 and extracted with EtOAc (3X). The combined organic layers are washed sequentially with water and brine, dried over MgSO_4 and concentrated *in vacuo* to afford 1.17 g (98%) of 1*H*-indazole-6-carboxylic acid as a tan solid: IR (diffuse reflectance) 3171, 3135, 3067, 3014, 2950, 2889, 2865, 1685, 1326, 1308, 1240, 960, 945, 762, 740 cm^{-1} ; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.4, 13.0, 8.2, 8.2, 7.9, 7.7.

Example 11(i) is obtained in 81% yield by coupling 1*H*-indazole-6-carboxylic acid with *exo*-(4*S*)-[2.2.1]-3-amine using conditions according to Example 10(i), making non-critical changes. The salt is then formed to obtain Example 11(i) in 77%

yield from the coupling to salt: ^1H NMR (400 MHz, CD_3OD) δ 8.15, 8.10, 7.88, 7.63, 6.71, 4.27-4.25, 3.74-3.69, 3.46-3.36, 3.23-3.21, 3.08, 2.24-2.14, 1.88-1.81.

Example 12: *N*-[(*exo*-4*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide:



To a stirred solution of ethyl [1,3]dioxolo[4,5-*c*]pyridine-6-carboxylate (see: Dallacker, F. Z. *Naturforsch.* 1979, 34b, 1729-1736.) (462 mg, 2.37 mmol) in EtOH (5 mL) is added NaOH (10 mL of a 5% aqueous solution). The mixture is heated to reflux for 1.5 h, followed by cooling to rt. The ethanol is removed *in vacuo*, and the remaining aqueous layer is acidified to pH=4 with 1N HCl, extracted with CH_2Cl_2 continuously for 2 days. The organic layer is concentrated to a white solid (315 mg, 80%): ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.12, 7.52, 6.21.

To a stirred solution of [1,3]dioxolo[4,5-*c*]pyridine-6-carboxylic acid (100 mg, 0.60 mmol) in anhydrous DMF (10 mL) in an ice bath is added sequentially DIEA (318 μL , 1.83 mmol), (3*R*, 4*S*)-1-azabicyclo[2.2.1]heptan-3-amine bis(hydro-*para*-toluenesulfonate) (273 mg, 0.60 mmol) and HATU (228 mg, 0.60 mmol). The mixture is stirred at 0°C for 30 min, followed by warming to rt and stirring overnight. The mixture is concentrated *in vacuo* to a yellow residue. The residue is partitioned between CHCl_3 -MeOH (90:10) and half saturated aqueous potassium carbonate solution. The aqueous layer is extracted with CHCl_3 -MeOH (90:10), and the combined organic layers are washed with brine, dried (MgSO_4), filtered and concentrated *in vacuo*. The crude product is purified by flash chromatography on silica gel. Elution with CHCl_3 -MeOH- NH_4OH (90:9:1) gives 150 mg (96%) of a white solid.

To a stirred solution of the amide (150 mg, 0.58 mmol) in MeOH (5 mL) is added fumaric acid (66 mg, 0.58 mmol). The mixture is warmed on a water bath to 40°C for 30 min, followed by removal of the solvent *in vacuo*. Acetone (10 mL) and water (0.1 mL) are added to the residue, which produced a white precipitate. The

solid precipitate is filtered, washed with acetone and dried *in vacuo* to afford 209 mg (92%) of Example 12(i) as a white solid: ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.61, 8.18, 7.55, 6.54, 6.25, 3.76, 3.06, 2.89-2.79, 2.63-2.58, 2.46, 1.68, 1.30.

5 The following examples can be prepared according to the coupling procedures discussed herein using the azabicyclic amines and acids discussed herein:

Example 21: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide.

Example 22: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-10 5-carboxamide.

Example 23: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-6-carboxamide.

Example 24: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-6-carboxamide.

15 **Example 25:** *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzothiazole-6-carboxamide.

Example 26: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)indane-5-carboxamide.

Example 27: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzodioxole-5-carboxamide.

20 **Example 28:** *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide.

Example 29: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-2-benzoisothiophene-5-benzamide.

Example 30: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1*H*-indazole-5-25 carboxamide.

Example 31: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1*H*-indazole-6-carboxamide.

Example 32: *N*-(1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide.

30 **Example 41:** *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzoxazole-5-carboxamide.

Example 42: *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-2-methyl-1,3-benzoxazole-5-carboxamide.

Example 43: *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzoxazole-6-carboxamide.

5 **Example 44:** *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-2-methyl-1,3-benzoxazole-6-carboxamide.

Example 45: *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzothiazole-6-carboxamide.

Example 46: *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)indane-5-carboxamide.

10 **Example 47:** *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzodioxole-5-carboxamide.

Example 48: *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide.

Example 49: *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-2-benzoisothiophene-5-
15 benzamide.

Example 50: *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1*H*-indazole-5-carboxamide.

Example 51: *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1*H*-indazole-6-carboxamide.

20 **Example 52:** *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide.

Example 61: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzoxazole-5-carboxamide.

Example 62: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-2-methyl-1,3-benzoxazole-5-
25 carboxamide.

Example 63: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzoxazole-6-carboxamide.

Example 64: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-2-methyl-1,3-benzoxazole-6-carboxamide.

Example 65: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzothiazole-6-carboxamide.

30 **Example 66:** *N*-(2-azabicyclo[2.2.1]hept-5-yl)indane-5-carboxamide.

Example 67: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzodioxole-5-carboxamide.

Example 68: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide.

Example 69: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-2-benzisothiophene-5-benzamide.

Example 70: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1*H*-indazole-5-carboxamide.

Example 71: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1*H*-indazole-6-carboxamide.

Example 72: *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-
5 carboxamide.

Example 81: *N*-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-benzoxazole-5-carboxamide.

Example 82: *N*-(2-azabicyclo[2.2.1]hept-6-yl))-2-methyl-1,3-benzoxazole-5-
carboxamide.

10 **Example 83:** *N*-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-benzoxazole-6-carboxamide.

Example 84: *N*-(2-azabicyclo[2.2.1]hept-6-yl))-2-methyl-1,3-benzoxazole-6-
carboxamide.

Example 85: *N*-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-benzothiazole-6-carboxamide.

Example 86: *N*-(2-azabicyclo[2.2.1]hept-6-yl))indane-5-carboxamide.

15 **Example 87:** *N*-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-benzodioxole-5-carboxamide.

Example 88: *N*-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-oxazolo[5,4-*c*]pyridine-6-
carboxamide.

Example 89: *N*-(2-azabicyclo[2.2.1]hept-6-yl))-2-benzisothiophene-5-benzamide.

Example 90: *N*-(2-azabicyclo[2.2.1]hept-6-yl))-1*H*-indazole-5-carboxamide.

20 **Example 91:** *N*-(2-azabicyclo[2.2.1]hept-6-yl))-1*H*-indazole-6-carboxamide.

Example 92: *N*-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-dioxolo[4,5-*c*]pyridine-6-
carboxamide.


Example 101: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzoxazole-5-
25 carboxamide.

Example 102: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzoxazole-5-
carboxamide.

Example 103: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzoxazole-6-
carboxamide.

30 **Example 104:** *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzoxazole-6-
carboxamide.

Example 105: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-
carboxamide•fumarate:



A mixture of benzothiazole-6-carboxylic acid (0.182 g, 1.02 mmol), *exo*-(3*R*,5*R*)-[3.2.1]-Amine (0.209 g, 1.05 mmol), THF (18 mL), DMF (4 mL) and DIEA (0.57 mL, 3.3 mmol) is cooled in an ice bath under N₂. HATU (0.388 g, 1.02 mmol) is then added and the mixture stirred at rt overnight. The mixture is then concentrated and the crude product is purified by chromatography (Biotage 40S, (1-9-90) NH₄OH-MeOH-CHCl₃). The product fractions are pooled and concentrated. The residue is treated with EtOH and fumaric acid (0.95 eq) and evaporated. The residue is treated with EtOAc and the solid collected washed with Et₂O and dried *in vacuo* to afford 0.332 g (81%) of the title compound. MS (EI) *m/z* 287 (M⁺).

Example 106: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]indane-5-carboxamide.

Example 107: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzodioxole-5-carboxamide.

Example 108: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide.

Example 109: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-benzisothiophene-5-benzamide.

Example 110: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-indazole-5-carboxamide.

Example 111: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-indazole-6-carboxamide.

Example 112: *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide.

Example 121: *N*-((3*R*)-1-azabicyclo[3.2.2]nonan-3-yl)-1,3-benzoxazole-5-carboxamide.

Example 122: *N*-((3*R*)-1-azabicyclo[3.2.2]nonan-3-yl)-1,3-benzothiazole-6-carboxamide.

Example 123: *N*-((3*R*)-1-azabicyclo[3.2.2]nonan-3-yl)indane-5-carboxamide.


Example 124: *N*-((3*R*)-1-azabicyclo[3.2.2]nonan-3-yl)-1,3-benzodioxole-5-carboxamide.

Example 125: *N*-[(3*R*)-1-azabicyclo[3.2.2]nonan-3-yl]-1*H*-indazole-6-carboxamide.

Example 126: *N*-[(3*R*)-1-azabicyclo[3.2.2]nonan-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide.


The benzothiazole and benzimidazole intermediates can be prepared using the methods as shown in Scheme 4 or Scheme 5, respectively. The benzoxazole intermediates can be prepared using methods described in Campaigne, E.; Van Verth, J. E., *J. Org. Chem.*, 1958, 23, 1344-1346, whereby the requisite *o*-aminophenol is treated with diethyl oxalate. An alternate preparation of these compounds utilizes an approach described in *Pol. J. Pharm.*, 1984, 683-688, wherein the *o*-aminophenol is treated with glycolic acid. The resultant alcohol is then oxidized with KMnO_4 to afford the desired benzoxazole-2-carboxylic acid derivative. Similar approaches can be followed to afford the desired benzothiazole and benzimidazole derivatives.

Scheme 4




15

Scheme 5




Alternatively, for where there is substitution on the imidazole:



The synthetic route to other compounds of interest is shown in Scheme 4. Heating C1010 in neat diethyl oxalate provides C1011. Alternatively, heating C1010 in neat glycolic acid provides an alcohol which is subsequently oxidized with KMnO_4 to afford C1012 (*Pol. J. Pharm.* **1984**, 683-688). In yet another approach to compounds of the present invention, 2-halonitroaryl or heteroaryl compounds are subjected to amines wherein a well documented ipso-displacement of the halogen group occurs to provide a nitro-derivative that can be reduced, using methods well known to those of ordinary skill in the art, yielding C1016. Finally, using methods described earlier, C1016 can be transformed into C1013 directly using diethyloxalate or into C1017 using glycolic acid followed by oxidation of the alcohol to the carboxylic acid.

The coupling of the Azabicyclo moiety occurs using either the carboxylic acids, such as C1012 or C1013, or the ethyl esters, such as C1001, C1011, or C1017, as shown in Scheme 6.


Scheme 6



2-Carboethoxy derivatives can be directly coupled to the amino-azabicyclo moiety upon heating in the ester in ethanol at reflux. An alternate route entails

subjecting the ester to hydrolysis providing a carboxylic acid. The carboxylic acid can then be coupled to the amino-azabicyclo moiety using a variety of amide bond coupling reagents.

5 **Example 1000:** *N*-[1-azabicyclo[2.2.1]hept-3-yl]-1,3-benzothiazole-2-carboxamide:



A solution of 2-aminothiophenol (10.7 mL, 0.1 mol) in diethyl oxalate (27.3 mL, 0.2 mol) is heated at reflux for 4 hr. The solution is cooled to rt and poured into a solution consisting of water (150 mL), conc. HCl (50 mL) and 95% EtOH (70 mL).

10 With stirring, the oil dissolved and a solid formed. The solution is cooled in an ice bath, the solid is collected by vacuum filtration and the solids are washed with a solution consisting of EtOH/water (25/75) to afford a dark solid. This material is purified by crystallization from hot (68 °C) ligroin to yield ethyl 2-benzothiazolecarboxylate (7.5 g, 36%): Elemental analysis for $C_{10}H_9NO_2S$: Calc: C, 57.95; H, 4.38; N, 6.76. Found: C, 57.99; H, 4.28; N, 6.78.

Using procedures discussed herein, ethyl 2-benzothiazolecarboxylate and the *exo*- or *endo*-[2.2.1]-Amine are coupled to give the desired compound.

20 Materials and Methods for Determining $\alpha 7$ nAChR Agonist Activity

Cell-based Assay for Measuring the EC_{50} of $\alpha 7$ nAChR Agonists

Construction and expression of the $\alpha 7$ -5HT₃ receptor:

25 The cDNA encoding the N-terminal 201 amino acids from the human $\alpha 7$ nAChR that contain the ligand binding domain of the ion channel is fused to the cDNA encoding the pore forming region of the mouse 5HT₃ receptor as described by Eisele JL, et al., Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities, Nature (1993), Dec. 2;366(6454):479-83, and
30 modified by Groppi, et al., WO 00/73431. The chimeric $\alpha 7$ -5HT₃ ion channel is inserted into pGS175 and pGS179 which contain the resistance genes for G-418 and

hygromycin B, respectively. Both plasmids were simultaneously transfected into SH-EP1 cells and cell lines were selected that were resistant to both G-418 and hygromycin B. Cell lines expressing the chimeric ion channel were identified by their ability to bind fluorescent α -bungarotoxin on their cell surface. The cells with the highest amount of fluorescent α -bungarotoxin binding were isolated using a Fluorescent Activated Cell Sorter (FACS). Cell lines that stably expressed the chimeric $\alpha 7$ -5HT₃ were identified by measuring fluorescent α -bungarotoxin binding after growing the cells in minimal essential medium containing nonessential amino acids supplemented with 10% fetal bovine serum, L-glutamine, 100 units/ml penicillin/streptomycin, 250 ng/mg fungizone, 400 μ g/ml hygromycin B, and 400 μ g/ml G-418 at 37° C with 6% CO₂ in a standard mammalian cell incubator for at least 4 weeks in continuous culture.

Assay of the activity of the chimeric $\alpha 7$ -5HT₃ receptor

To assay the activity of the $\alpha 7$ -5HT₃ ion channel, cells expressing the channel were plated into each well of either a 96 or 384 well dish (Corning #3614) and grown to confluence prior to assay. On the day of the assay, the cells were loaded with a 1:1 mixture of 2 mM Calcium Green 1, AM (Molecular Probes) dissolved in anhydrous DMSO and 20% pluronic F-127 (Molecular Probes). This solution is added directly to the growth media of each well to achieve a final concentration 2 μ M. The cells were incubated with the dye for 60 min at 37° C and then washed with a modified version of Earle's balanced salt solution (MMEBSS) as described in WO 00/73431. The ion conditions of the MMEBSS is adjusted to maximize the flux of calcium ion through the chimeric $\alpha 7$ -5HT₃ ion channel as described in WO 00/73431. The activity of compounds on the chimeric $\alpha 7$ -5HT₃ ion channel is analyzed on FLIPR. The instrument is set up with an excitation wavelength of 488 nanometers using 500 milliwatts of power. Fluorescent emission is measured above 525 nanometers with an appropriate F-stop to maintain a maximal signal to noise ratio. Agonist activity of each compound is measured by directly adding the compound to cells expressing the chimeric $\alpha 7$ -5HT₃ ion channel and measuring the resulting increase in intracellular calcium that is caused by the agonist-induced activation of the chimeric ion channel. The assay is quantitative such that concentration-dependent increase in intracellular calcium is measured as concentration-dependent change in Calcium Green

fluorescence. The effective concentration needed for a compound to cause a 50% maximal increase in intracellular calcium is termed the EC₅₀. The following examples of the present invention have EC₅₀ values from about 180 nM to about 5700 nM:

Example 1, Example 5, Example 6, Example 7, Example 10, Example 11, Example 12, and Example 105.

Binding Constants:

Another way for measuring $\alpha 7$ nAChR agonist activity is to determine binding constants of a potential agonist in a competition binding assay. For $\alpha 7$ nAChR agonists, there is good correlation between functional EC₅₀ values using the chimeric $\alpha 7$ -5HT₃ ion channel as a drug target and binding affinity of compounds to the endogenous $\alpha 7$ nAChR.

Membrane Preparation.

Male Sprague-Dawley rats (300-350g) are sacrificed by decapitation and the brains (whole brain minus cerebellum) are dissected quickly, weighed and homogenized in 9 volumes/g wet weight of ice-cold 0.32 M sucrose using a rotating pestle on setting 50 (10 up and down strokes). The homogenate is centrifuged at 1,000 x g for 10 minutes at 4 °C. The supernatant is collected and centrifuged at 20,000 x g for 20 minutes at 4 °C. The resulting pellet is resuspended to a protein concentration of 1 - 8 mg/mL. Aliquots of 5 mL homogenate are frozen at -80 °C until needed for the assay. On the day of the assay, aliquots are thawed at rt and diluted with Kreb's - 20 mM Hepes buffer pH 7.0 (at rt) containing 4.16 mM NaHCO₃, 0.44 mM KH₂PO₄, 127 mM NaCl, 5.36 mM KCl, 1.26 mM CaCl₂, and 0.98 mM MgCl₂, so that 25 - 150 μ g protein are added per test tube. Proteins are determined by the Bradford method (Bradford, M.M., *Anal. Biochem.*, 72, 248-254, 1976) using bovine serum albumin as the standard.

Binding Assay.

For saturation studies, 0.4 mL homogenate are added to test tubes containing buffer and various concentrations of radioligand, and are incubated in a final volume of 0.5 mL for 1 hour at 25 °C. Nonspecific binding is determined in tissues incubated in parallel in the presence of 0.05 mls MLA for a final concentration of 1 μ M, added

before the radioligand. In competition studies, drugs are added in increasing concentrations to the test tubes before addition of 0.05 mls [^3H]-MLA for a final concentration 3.0 to 4.0 nM. The incubations are terminated by rapid vacuum filtration through Whatman GF/B glass filter paper mounted on a 48 well Brandel cell harvester. Filters are pre-soaked in 50 mM Tris HCl pH 7.0 - 0.05 % polyethylenimine. The filters are rapidly washed two times with 5 mL aliquots of cold 0.9% saline and then counted for radioactivity by liquid scintillation spectrometry.


Data Analysis.

In competition binding studies, the inhibition constant (K_i) is calculated from the concentration dependent inhibition of [^3H]-MLA binding obtained from non-linear regression fitting program according to the Cheng-Prusoff equation (Cheng, Y.C. and Prusoff, W.H., *Biochem. Pharmacol.*, 22, p. 3099-3108, 1973). Hill coefficients were obtained using non-linear regression (GraphPad Prism sigmoidal dose-response with variable slope).

15

What is claimed:

1. A compound of the Formula I:




Formula I

5 wherein X is O, or S;

Each R₁ is H, alkyl, cycloalkyl, halogenated alkyl, substituted phenyl, or substituted naphthyl;

Azabicyclo is




10 R₀ is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl;
Each R₂ is independently alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl, or R₂ is absent provided that k₂, k₅, or k₆ is 0;

k₂ is 0 or 1;

k₅ and k₆ are independently 0, 1, or 2;

15 R₂₋₃ is H, alkyl, halogenated alkyl, substituted alkyl, F, Cl, Br, or I;

W⁰ is a bicyclic moiety and is



W is C(H) where

V---Z---Y is selected from O-C(R₃)=N, O-C(R₅)₂-N(R₄), O-C(R₅)₂-S,
 O-N=C(R₅), O-C(R₅)(R₈)-O, O-C(R₅)₂-O, C(R₅)₂-O-C(R₅)₂, S-C(R₃)=N,
 S-C(R₅)₂-N(R₄), S-N=C(R₅), N=C(R₃)-O, N=C(R₃)-S, N=C(R₃)-N(R₄),
 N(R₄)-N=C(R₅), N(R₄)-C(R₅)₂-O, N(R₄)-C(R₅)₂-S, N(R₄)-C(R₅)₂-N(R₄),
 5 C(R₅)₂-O-N(R₄), C(R₅)₂-S-C(R₅)₂, C(R₅)₂-N(R₄)-C(R₅)₂, C(R₅)₂-N(R₄)-O,
 C(R₅)₂-N(R₄)-S, C(R₅)=N-O, C(R₅)=N-S, C(R₅)=N-N(R₄),
 C(R₅)(R₁₇)-C(R₃)(R₁₇)-C(R₅)(R₁₇), or C(R₅)₂-C(R₃)(R₅)-C(R₅)₂;

W is N where

V---Z---Y is selected from O-C(R₃)=N, O-C(R₅)₂-N(R₄), O-C(R₅)₂-S,
 10 O-N=C(R₅), O-C(R₅)₂-O, S-C(R₃)=N, S-C(R₅)₂-N(R₄), S-N=C(R₅), N=C(R₃)-O,
 N=C(R₃)-S, N=C(R₃)-N(R₄), N(R₄)-N=C(R₃), N(R₄)-C(R₅)₂-O, N(R₄)-C(R₅)₂-S,
 N(R₄)-C(R₅)₂-N(R₄), C(R₅)₂-O-N(R₄), C(R₅)₂-N(R₄)-O, C(R₅)₂-N(R₄)-S,
 C(R₅)=N-O, C(R₅)=N-S, C(R₃)=N-N(R₄), C(R₅)=C(R₃)-O, C(R₅)=C(R₃)-S,
 C(R₅)=C(R₅)-N(R₄), C(R₅)=C(R₅)-C(R₅)₂, or C(R₅)₂-C(R₃)(R₅)-C(R₅)₂;

15 W¹, W², W³, and W⁴ are each independently N or C(R₂₁), provided that no
 more than two of W¹, W², W³, and W⁴ are N and further provided when more than
 two of W¹, W², W³, and W⁴ are C(R₂₁) that no more than two R₂₁ are other than H;

J is N(R₂₃), S, or O;

Q is N(R₁₉), O, or S;


20 Each R₃ is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted
 alkyl, cycloalkyl, lactam heterocycloalkyl, phenoxy, substituted phenoxy, R₇, R₉,
 -N(R₄)-aryl, -N(R₄)-halogenated phenyl, -N(R₄)-halogenated naphthyl,
 -O-halogenated phenyl, -O-substituted phenyl, -O-halogenated naphthyl,
 -O-substituted naphthyl, -S-halogenated phenyl, -S-substituted phenyl, -S-halogenated
 25 naphthyl, -S-substituted naphthyl, or alkyl substituted on the ω carbon with R₁₅ where
 said ω carbon is determined by counting the longest carbon chain of the alkyl moiety
 with the C-1 carbon being the carbon attached to the bicyclic moiety W⁰ and the ω
 carbon being the carbon furthest, e.g., separated by the greatest number of carbon
 atoms in the chain, from said C-1 carbon;

30 Each R₄ is H, or alkyl;


Each R₅ is independently H, F, alkyl, substituted alkyl, halogenated alkyl,
 alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl,
 halogenated alkynyl, cycloalkyl, -C(O)NH₂, -CO₂R₁, or aryl;

R_6 is H, F, Br, I, Cl, -CN, -CF₃, -OR₁₆, -SR₁₆, or -N(R₁₆)₂;

R_7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of -O-, =N-, -N(R₁₉)-, and -S-, and having 0-1 substituent selected from R₂₀ and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R_7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula




wherein A₁ is O, S, or NR₁₉,



10

wherein A is CR₁₈ or N, A₂ and A₃ are independently selected from CR₁₈, C(R₁₈)₂, O, S, N, or NR₁₉, provided that both A₂ and A₃ are not simultaneously O, simultaneously S, or simultaneously O and S, or



15 wherein A₂ and A₃ are independently selected from CR₁₈, C(R₁₈)₂, O, S, N, or NR₁₉, and A is CR₁₈ or N, each 9-membered fused-ring moiety having 0-1 substituent selected from R₂₀ and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;

20

Each R₈ is independently F, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, cycloalkyl, -C(O)NH₂, -CO₂R₁, or aryl;

R_9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R₂₀ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R_9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyI or

25

isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R₂₀ and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond directly or indirectly attached to the core molecule where valency allows;

Each R₁₀ is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R₁₃, cycloalkyl substituted with 1 substituent selected from R₁₃, heterocycloalkyl substituted with 1 substituent selected from R₁₃, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;

Each R₁₁ is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;

R₁₃ is -OR₁₁, -SR₁₁, -N(R₁₁)₂, -C(O)R₁₁, -C(O)NR₁₁R₁₁, -CN, -CF₃, -NR₁₁C(O)R₁₁, -S(O)₂N(R₁₁)₂, -NR₁₁S(O)₂R₁₁, or -NO₂;

R₁₅ is aryl, R₇, or R₉;

R₁₆ is H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, substituted phenyl, or substituted naphthyl;

One of R₁₇ is H, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, -CN, F, Br, Cl, I, -OR₁, -C(O)NH₂, -NHR₁, -SR₁, -CO₂R₁, aryl, R₇, or R₉, and each of the other two R₁₇ is independently alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, -CN, F, Br, Cl, I, -OR₁, -C(O)NH₂, -NHR₁, -SR₁, -CO₂R₁, aryl, R₇, or R₉;

Each R₁₈ is independently selected from H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₁₁, -SR₁₁, -NR₁₁R₁₁, -C(O)R₁₁, -NO₂, -C(O)N(R₁₁)₂, -CN, -NR₁₁C(O)R₁₁, -S(O)₂N(R₁₁)₂, F, Cl, Br, or I, -NR₁₁S(O)₂R₁₁, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₁₁, -SR₁₁, -NR₁₁R₁₁, -C(O)R₁₁, -NO₂, -C(O)NR₁₁R₁₁, -CN, -NR₁₁C(O)R₁₁, -S(O)₂NR₁₁R₁₁, or -NR₁₁S(O)₂R₁₁, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;

R₁₉ is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R₂₀ and further having 0-3 substituents independently selected from F, Cl, Br, or I;

5 R₂₀ is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, -OR₁₁, -SR₁₁, -NR₁₁R₁₁, -C(O)R₁₁, -C(O)NR₁₁R₁₁, -CN, -NR₁₁C(O)R₁₁, -S(O)₂NR₁₁R₁₁, -NR₁₁S(O)₂R₁₁, -NO₂, alkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R₁₃, cycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, 10 or R₁₃, or heterocycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or -R₁₃;

R₂₁ is H, F, Cl, Br, I, alkyl, substituted alkyl, halogenated alkyl, cycloalkyl, -CN, -NR₂₂R₂₂, -OR₂₂, or -SR₂₂;

Each R₂₂ is independently H, alkyl, substituted alkyl, cycloalkyl, halogenated 15 alkyl, substituted cycloalkyl, heterocycloalkyl, or substituted heterocycloalkyl;

R₂₃ is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, naphthyl, substituted naphthyl, R₇, or R₉;

20 or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein X is O.

3. The compound of claim 2, wherein R₁ is H, alkyl, or cycloalkyl.

4. The compound of claim 3, wherein W⁰ is (a).

5. The compound of claim 4, wherein (a) is 1,3-oxazolo[4,5-c]pyridin-6-yl, 1,3-oxazolo[5,4-c]pyridin-6-yl, 1,3-dioxolo[4,5-c]pyridin-6-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,2-benzisothiazol-5-yl, 1,2-benzisothiazol-6-yl, 1,3-thiazolo[4,5-c]pyridin-6-yl, 1,3-thiazolo[5,4-c]pyridin-6-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzodioxol-5-yl, 1*H*-benzimidazole-5-yl, 1*H*-indazol-5-yl, 1*H*-indazol-6-yl, or indan-5-yl, any of which is optionally substituted with lower 30 cycloalkyl or lower alkyl optionally substituted with to 4 halogens, and further optionally substituted with up to 1 substituent selected from -OR₁₀, -N(R₁₀)₂, -C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀, -NR₁₀S(O)₂R₁₀, wherein each R₁₀ is independently selected from lower alkyl or halogenated lower alkyl.

6. The compound of claim 5, wherein Azabicyclo is I, II, V, or VI.
7. The compound of claim 6, wherein each k_2 , k_5 , and k_6 is independently 0 or 1.
8. The compound of claim 7, wherein R_2 is alkyl, or R_2 is absent provided that
- 5 Azabicyclo is II, V or VI and further provided that k_2 , k_5 , and k_6 are 0.
9. The compound of claim 8, wherein R_1 is H or lower alkyl, and wherein R_2 is lower alkyl or is absent provided that k_2 , k_5 , or k_6 is 0.
10. The compound of claim 9, wherein the compound is
N-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide;
N-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzothiazole-6-carboxamide;
N-[(*exo*-4*S*)-1-azabicyclo[2.2.1]hept-3-yl]-indane-5-carboxamide;
N-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzodioxole-5-carboxamide;
N-[(*exo*-4*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1*H*-indazole-5-carboxamide;
N-[(*exo*-4*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1*H*-indazole-6-carboxamide;
15 *N*-[(*exo*-4*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide; or a pharmaceutically acceptable salt thereof, provided that the compound is the pure enantiomer or racemic mixture thereof.
- 20 11. The compound of claim 9, wherein the compound is
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzoxazole-5-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzoxazole-6-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-2-methyl-1,3-benzoxazole-6-carboxamide;
25 *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzothiazole-6-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)indane-5-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzodioxole-5-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
30 *N*-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1*H*-indazole-5-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1*H*-indazole-6-carboxamide;
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;

- N*-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
N-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-6-carboxamide;
N-(*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-6-carboxamide;
N-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
5 *N*-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-5-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzoxazole-6-
10 carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-2-methyl-1,3-benzoxazole-6-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzothiazole-6-carboxamide;
15 *N*-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)indane-5-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzodioxole-5-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
20 *N*-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1*H*-indazole-5-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1*H*-indazole-6-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzoxazole-5-carboxamide;
25 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzoxazole-5-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzoxazole-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzoxazole-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]indane-5-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzodioxole-5-carboxamide;
30 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-indazole-5-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-indazole-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;

- N -((3R)-1-azabicyclo[3.2.2]nonan-3-yl)-1,3-benzoxazole-5-carboxamide;
 N -((3R)-1-azabicyclo[3.2.2]nonan-3-yl)-1,3-benzothiazole-6-carboxamide;
 N -((3R)-1-azabicyclo[3.2.2]nonan-3-yl)indane-5-carboxamide;
 N -((3R)-1-azabicyclo[3.2.2]nonan-3-yl)-1,3-benzodioxole-5-carboxamide;
 5 N -[(3R)-1-azabicyclo[3.2.2]nonan-3-yl]-1*H*-indazole-6-carboxamide;
 N -[(3R)-1-azabicyclo[3.2.2]nonan-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
 or a pharmaceutically acceptable salt thereof, provided that the compound is the pure enantiomer or racemic mixture thereof.

- 10 12. The compound of claim 9, wherein the compound is
 N -[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1,2-benzisothiazole-6-carboxamide;
 N -[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1,2-benzisothiazole-5-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-indazole-5-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1*H*-indazole-6-carboxamide;
 15 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1*H*-indazole-5-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethyl-1*H*-indazole-6-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethyl-1*H*-indazole-5-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,2-benzisothiazole-6-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,2-benzisothiazole-5-carboxamide;
 20 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethyl-1,2-benzisothiazole-6-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethyl-1,2-benzisothiazole-5-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1,2-benzisothiazole-6-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1,2-benzisothiazole-5-carboxamide;
 25 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyclopropyl-1,3-benzoxazole-6-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyclopropyl-1,3-benzoxazole-5-carboxamide;
 30 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyclopropyl-1,3-benzothiazole-6-carboxamide;
 N -[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyclopropyl-1,3-benzothiazole-5-carboxamide;

- N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzothiazole-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzothiazole-5-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethyl-1,3-benzothiazole-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethyl-1,3-benzothiazole-5-carboxamide;
5 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1,3-benzodioxole-5-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-ethyl-1,3-benzodioxole-5-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2,2-dimethyl-1,3-benzodioxole-5-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-benzimidazole-5-carboxamide;
10 *N*-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-thiazolo[5,4-*c*]pyridine-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-thiazolo[4,5-*c*]pyridine-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-oxazolo[4,5-*c*]pyridine-6-carboxamide;
or a pharmaceutically acceptable salt thereof, provided that the compound is the pure
15 enantiomer or racemic mixture thereof.

13. The compound of claim 5, wherein Azabicyclo is III, or IV.

14. The compound of claim 13, wherein R_{2,3} is H, or alkyl.

15. The compound of claim 14, wherein the compound is

- 20 *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzoxazole-5-carboxamide;
N-(2-azabicyclo[2.2.1]hept-5-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
N-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzoxazole-6-carboxamide;
N-(2-azabicyclo[2.2.1]hept-5-yl)-2-methyl-1,3-benzoxazole-6-carboxamide;
N-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzothiazole-6-carboxamide;
25 *N*-(2-azabicyclo[2.2.1]hept-5-yl)indane-5-carboxamide;
N-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzodioxole-5-carboxamide;
N-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
N-(2-azabicyclo[2.2.1]hept-5-yl)-1*H*-indazole-5-carboxamide;
N-(2-azabicyclo[2.2.1]hept-5-yl)-1*H*-indazole-6-carboxamide;
30 *N*-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl)-1,3-benzoxazole-5-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl)-2-methyl-1,3-benzoxazole-5-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl)-1,3-benzoxazole-6-carboxamide;

- N*-(2-azabicyclo[2.2.1]hept-6-yl))-2-methyl-1,3-benzoxazole-6-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-benzothiazole-6-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl))indane-5-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-benzodioxole-5-carboxamide;
5 *N*-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-oxazolo[5,4-*c*]pyridine-6-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl))-1*H*-indazole-5-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl))-1*H*-indazole-6-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl))-1,3-dioxolo[4,5-*c*]pyridine-6-carboxamide; or a
pharmaceutically acceptable salt thereof.

10

16. The compound of claim 3, wherein W^0 is (b).
17. The compound of claim 16, wherein (b) is 2-benzisothiophen-5-yl, 2*H*-isoindole-5-yl, or 2-benzofuran-5-yl, any of which is optionally substituted with lower
15 cycloalkyl or lower alkyl optionally substituted with to 4 halogens, and further
optionally substituted with up to 1 substituent selected from $-OR_{10}$, $-N(R_{10})_2$,
 $-C(O)NR_{10}R_{10}$, $-CN$, $-NR_{10}C(O)R_{10}$, $-NR_{10}S(O)_2R_{10}$, wherein each R_{10} is
independently selected from lower alkyl or halogenated lower alkyl.
- 20 18. The compound of claim 17, wherein Azabicyclo is I, II, V, or VI.
19. The compound of claim 18, wherein each k_2 , k_5 , and k_6 is independently 0 or
1.
20. The compound of claim 19, wherein R_2 is alkyl, or R_2 is absent provided that
Azabicyclo is II, V or VI and further provided that k_2 , k_5 , and k_6 are 0.
- 25 21. The compound of claim 20, wherein R_1 is H or lower alkyl, and wherein R_2 is
lower alkyl or is absent provided that k_2 , k_5 , or k_6 is 0.
22. The compound of claim 21, wherein the compound is
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-2-benzisothiophene-5-benzamide;
N-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-2-benzisothiophene-5-benzamide;
30 *N*-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-2-benzisothiophene-5-
benzamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-benzisothiophene-5-benzamide;
N-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-2-benzofuran-5-carboxamide;

N-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-2*H*-isoindole-5-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2-benzofuran-5-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-2*H*-isoindole-5-carboxamide; or a
pharmaceutically acceptable salt thereof, provided that the compound is the pure
5 enantiomer or racemic mixture thereof.

23. The compound of claim 17, wherein Azabicyclo is III, or IV.
24. The compound of claim 23, wherein R_{2,3} is H, or alkyl.
25. The compound of claim 24, wherein the compound is
10 *N*-(2-azabicyclo[2.2.1]hept-5-yl)-2-benzoisothiophene-5-benzamide;
N-(2-azabicyclo[2.2.1]hept-6-yl)-2-benzoisothiophene-5-benzamide; or a
pharmaceutically acceptable salt thereof.
26. The compound of claim 3, wherein W⁰ is (c).
15 27. The compound of claim 26, wherein (c) is 1,3-benzothiazol-2-yl, or 1*H*-
imidazo[4,5-*c*]pyridin-6-yl, either of which is optionally substituted with lower alkyl,
lower substituted alkyl, or lower halogenated alkyl.
28. The compound of claim 27, wherein Azabicyclo is I, II, V, or VI.
20 29. The compound of claim 28, wherein each k₂, k₅, and k₆ is independently 0 or
1.
30. The compound of claim 29, wherein R₂ is alkyl, or R₂ is absent provided that
Azabicyclo is II, V or VI and further provided that k₂, k₅, and k₆ are 0.
31. The compound of claim 30, wherein R₁ is H or lower alkyl, and wherein R₂ is
25 lower alkyl or is absent provided that k₂, k₅, or k₆ is 0.
32. The compound of claim 31, wherein the compound is
N-(1-(6-methyl)-azabicyclo[2.2.2]oct-3-yl)-1,3-benzothiazole-2-carboxamide;
N-[*exo*-4(*S*)-1-azabicyclo[2.2.1]hept-3-yl]-1,3-benzothiazole-2-carboxamide;
N-(*exo*-4(*S*)-1-(6-methyl)-azabicyclo[2.2.1]hept-3-yl)-1,3-benzothiazole-2-
30 carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-2-carboxamide;
N-[(3*R*,5*R*)-1-azabicyclo[3.2.1]oct-3-yl]-1*H*-imidazo[4,5-*c*]pyridine-6-carboxamide;
N-[(3*R*)-1-azabicyclo[3.2.2]nonan-3-yl]-1,3-benzothiazole-2-carboxamide; or a

pharmaceutically acceptable salt thereof, provided that the compound is the pure enantiomer or racemic mixture thereof.

33. The compound of claim 27, wherein Azabicyclo is III, or IV.

5 34. The compound of claim 33, wherein $R_{2,3}$ is H, or alkyl.

35. The compound of claim 34, wherein the compound is
N-(2-azabicyclo[2.2.1]hept-5-yl)-1,3-benzothiazole-2-carboxamide;
N-(2-azabicyclo[2.2.1]hept-6-yl)-1,3-benzothiazole-2-carboxamide; or a
pharmaceutically acceptable salt thereof.

10

36. A pharmaceutical composition comprising a compound according to any one of claims 1-35, an anti-psychotic agent, and a pharmaceutically acceptable excipient.

37. The pharmaceutical composition according to claim 36, wherein said
compound and said agent are to be independently administered rectally, topically,
15 orally, sublingually, or parenterally for a therapeutically effective interval.

38. The pharmaceutical composition according to claim 36, wherein said
compound is administered in an amount of from about 0.001 to about 100 mg/kg of
body weight of said mammal per day.

39. The pharmaceutical composition according to claim 36, wherein said
20 compound is administered in an amount of from about 0.1 to about 50 mg/kg of body
weight of said mammal per day.

40. The pharmaceutical composition according to claim 36, comprising a
compound according to any one of claims 1-35 and a pharmaceutically acceptable
excipient.

25 41. The pharmaceutical composition according to claim 40, wherein said
compound is administered rectally, topically, orally, sublingually, or parenterally for a
therapeutically effective interval.

42. The pharmaceutical composition according to claim 40, wherein said
compound is administered in an amount of from about 0.001 to about 100 mg/kg of
30 body weight of said mammal per day.

43. The pharmaceutical composition according to claim 40, wherein said
compound is administered in an amount of from about 0.1 to about 50 mg/kg of body
weight of said mammal per day.

44. Use of a compound according to any one of claims 1-35 for the preparation of a medicament for treating a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist.

45. The use according to claim 44, wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia.

46. The use according to claim 44, wherein the disease or condition is schizophrenia or psychosis.

47. The use of claim 46, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist and an anti-psychotic agent for a therapeutically effective interval.

48. The use according to claim 44, wherein the disease or condition is depression, anxiety, general anxiety disorders, or post traumatic stress disorder.

49. The use according to claim 44, wherein the disease or condition is attention deficit disorder, or attention deficit hyperactivity disorder.

50. The use according to claim 44, wherein the disease or condition is mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related

macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

51. A method for treating a disease or condition in a mammal in need thereof,
5 wherein the mammal would receive symptomatic relief from the administration of an $\alpha 7$ nicotinic acetylcholine receptor agonist comprising administering to the mammal a therapeutically effective amount of a compound according to any one of claims 1-35.

52. The method according to claim 51, wherein the disease or condition is
10 cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia.

53. The method according to claim 51, wherein the disease or condition is
15 schizophrenia or psychosis.

54. The method of claim 53, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist and an anti-psychotic agent for a therapeutically effective interval.

20 55. The method according to claim 51, wherein the disease or condition is depression, or anxiety and general anxiety disorders and post traumatic stress disorder.

56. The method according to claim 51, wherein the disease or condition is
25 attention deficit disorder, or attention deficit hyperactivity disorder.

57. The method according to claim 51, wherein the disease or condition is mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated
30 with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking

cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/31579

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D453/00 C07D487/08 C07D498/04 C07D519/00 C07D451/04
C07D471/08 A61K31/445 //(C07D487/08, 209:00, 209:00),
(C07D498/04, 221:00, 263:00), (C07D519/00, 209:00, 209:00, 221:00,

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 327 335 A (A. H. ROBINS CO., INC.) 9 August 1989 (1989-08-09) claims 1-10	1-57
X	A. ORJALES ET AL.: "Benzimidazole-2-carboxylic acid amides and esters: a new structural class of 5-HT ₃ ligands" EUR. J. MED. CHEM., vol. 34, no. 5, 1999, pages 415-422, XP002225452 cited in the application * Compounds of formula 13 *	1-57
X	DE 37 24 059 A (SANDOZ-PATENT GMBH) 18 February 1988 (1988-02-18) claims 1-16	1-57

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

18 December 2002

Date of mailing of the international search report

13/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/31579

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 317:00), (C07D519/00, 209:00, 209:00, 221:00, 263:00), (C07D519/00, 221:00, 221:00, 221:00, 317:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 605 652 A (W. J. WELSTEAD, JR.) 12 August 1986 (1986-08-12) cited in the application claims 1-19	1-57
Y	WO 01 36417 A (ASTRAZENECA AB) 25 May 2001 (2001-05-25) cited in the application claims 1-42	1-57
Y	WO 01 60821 A (ASTRAZENECA AB) 23 August 2001 (2001-08-23) cited in the application claims 1-40	1-57
Y	US 5 686 461 A (A. CUGOLA ET AL.) 11 November 1997 (1997-11-11) claims 1-10	1-57
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

G document member of the same patent family

Date of the actual completion of the international search

18 December 2002

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/31579

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 920 227 A (J. C. PELLETIER ET AL.) 24 April 1990 (1990-04-24) cited in the application claims 1-8 ----	1-57
Y	US 4 920 219 A (J. C. PELLETIER ET AL.) 24 April 1990 (1990-04-24) cited in the application claims 1-7 ----	1-57
Y	PATENT ABSTRACTS OF JAPAN vol. 017, no. 025, 18 January 1993 (1993-01-18) & JP 04 247081 A (TAKEDA CHEM. IND., LTD.), 3 September 1992 (1992-09-03) abstract ----	1-57
X	EP 0 323 077 A (JOHN WYETH & BROTHER LTD.) 5 July 1989 (1989-07-05) cited in the application claims 1-13 -----	1-57

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/31579

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 327335	A	09-08-1989	US 4863919 A	05-09-1989
			AT 81457 T	15-10-1992
			AU 629197 B2	01-10-1992
			AU 2950689 A	03-08-1989
			CA 1320448 A1	20-07-1993
			DE 68903178 D1	19-11-1992
			DE 68903178 T2	18-03-1993
			DK 42589 A	02-08-1989
			EP 0327335 A1	09-08-1989
			ES 2045402 T3	16-01-1994
			GR 3006764 T3	30-06-1993
			IL 88434 A	06-09-1992
			JP 1226818 A	11-09-1989
			NZ 227794 A	23-12-1991
			PH 25906 A	19-12-1991
			PT 89575 A , B	04-10-1989
			ZA 8809109 A	30-08-1989
DE 3724059	A	18-02-1988	AT 396870 B	27-12-1993
			AT 191287 A	15-05-1993
			AU 642210 B2	14-10-1993
			AU 7194691 A	09-05-1991
			AU 637878 B2	10-06-1993
			AU 7291091 A	16-05-1991
			AU 610074 B2	16-05-1991
			AU 7619087 A	04-02-1988
			BE 1005921 A4	15-03-1994
			CA 1327750 A1	15-03-1994
			CA 1334075 A1	24-01-1995
			CH 675072 A5	31-08-1990
			CY 1753 A	03-06-1994
			CY 1754 A	03-06-1994
			CY 1755 A	03-06-1994
			DE 3724059 A1	18-02-1988
			DK 392487 A	31-01-1988
			ES 2010227 A6	01-11-1989
			ES 2016440 A6	01-11-1990
			FI 873280 A	31-01-1988
			FR 2602142 A1	05-02-1988
			GB 2193633 A , B	17-02-1988
			GB 2231264 A , B	14-11-1990
			GB 2231265 A , B	14-11-1990
			GR 871212 A1	15-12-1987
			HK 2694 A	21-01-1994
			HK 2994 A	21-01-1994
			HK 4694 A	28-01-1994
			HU 45895 A2	28-09-1988
			IE 61103 B1	05-10-1994
			IL 83363 A	08-07-1993
			IL 96796 A	31-07-1994
			IL 96797 A	29-12-1994
			IT 1218150 B	12-04-1990
			JP 2632858 B2	23-07-1997
			JP 63041429 A	22-02-1988
			KR 9514445 B1	28-11-1995
			LU 86950 A1	02-02-1988
			NL 8701682 A	16-02-1988
			NO 873133 A	01-02-1988

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/31579

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 3724059	A	NZ 221226 A	26-07-1990
		SE 504184 C2	02-12-1996
		SE 8702980 A	28-04-1988
		SG 135193 G	31-03-1994
		SG 135293 G	31-03-1994
		SG 135693 G	31-03-1994
		US 5561149 A	01-10-1996
US 4605652	A 12-08-1986	AT 88891 T	15-05-1993
		AU 589155 B2	05-10-1989
		AU 5267286 A	07-08-1986
		CA 1273297 A1	28-08-1990
		DE 3688377 D1	09-06-1993
		DE 3688377 T2	21-10-1993
		EP 0190920 A2	13-08-1986
		JP 1932546 C	26-05-1995
		JP 6062414 B	17-08-1994
		JP 61183223 A	15-08-1986
		PH 22646 A	28-10-1988
WO 0136417	A 25-05-2001	AU 1907301 A	30-05-2001
		BR 0015624 A	30-07-2002
		EP 1233964 A1	28-08-2002
		NO 20022289 A	24-06-2002
		WO 0136417 A1	25-05-2001
		SK 6772002 A3	10-09-2002
WO 0160821	A 23-08-2001	AU 3259401 A	27-08-2001
		EP 1259508 A1	27-11-2002
		NO 20023917 A	16-09-2002
		WO 0160821 A1	23-08-2001
US 5686461	A 11-11-1997	AU 6257594 A	26-09-1994
		EP 0699186 A1	06-03-1996
		JP 8507300 T	06-08-1996
		WO 9420465 A1	15-09-1994
		ZA 9401483 A	11-11-1994
US 4920227	A 24-04-1990	NONE	
US 4920219	A 24-04-1990	AU 4743990 A	26-06-1990
		WO 9006113 A1	14-06-1990
		US 5063230 A	05-11-1991
JP 04247081	A 03-09-1992	NONE	
EP 323077	A 05-07-1989	AT 67200 T	15-09-1991
		AT 107304 T	15-07-1994
		AU 2670288 A	29-06-1989
		CA 1334095 A1	24-01-1995
		DE 3850255 D1	21-07-1994
		DE 3850255 T2	22-09-1994
		DE 3864807 D1	17-10-1991
		DK 82793 A	08-07-1993
		DK 710488 A	25-06-1989
		EP 0323077 A1	05-07-1989
		EP 0361629 A2	04-04-1990
		ES 2051867 T3	01-07-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/31579

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 323077	A	ES 2053959 T3	01-08-1994
		FI 885917 A ,B,	25-06-1989
		GB 2213816 A ,B	23-08-1989
		GB 2225574 A ,B	06-06-1990
		GR 3002701 T3	25-01-1993
		HU 204267 B	30-12-1991
		IE 63474 B1	19-04-1995
		IE 62231 B1	11-01-1995
		IL 88644 A	13-05-1993
		JP 1203365 A	16-08-1989
		JP 2588265 B2	05-03-1997
		KR 9709588 B1	14-06-1997
		PH 27437 A	02-07-1993
		PT 89286 A ,B	29-12-1989
		US 4983600 A	08-01-1991
		US 5106843 A	21-04-1992
		ZA 8809210 A	29-08-1990
		ZA 8905052 A	29-08-1990
		HU 53101 A2	28-09-1990